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Resumo 
Leishmaniose é uma doença tropical negligenciada causada pelo parasita Leishmania 
e é transmitida a humanos e cães pela mosca da areia fêmea Phlebotominae. A forma 
mais severa da doença é a leishmaniose visceral e é fatal se não tratada, estimando-se 
até 30 000 de mortes por ano. Devido a vários fatores como alterações climáticas e 
migração, o número de casos de leishmaniose tem vindo a aumentar. Outro problema 
é a falta de especificidade dos métodos de diagnóstico atuais, que resultam em falsos 
resultados. Indivíduos infetados, mas sem sintomas, são potenciais propagadores desta 
doença. Neste contexto, existe uma necessidade emergente de diagnóstico simples e 
eficiente capaz de fazer triagem da doença e consequentemente controlo da sua 
disseminação. 
Neste trabalho, pretende-se desenvolver um imunossensor imobilizando biomarcadores 
de soros caninos em elétrodos impressos, já que estes são descartáveis, baratos, fáceis 
de usar e de resposta rápida.  
Técnicas eletroanalíticas, como voltametria cíclica e potenciometria, são usadas para a 
caracterização dos imunossensores. O protocolo usado na imobilização da proteína 
baseia-se na imobilização do antigénio pela cauda de histidina (atualmente a proteína 
recombinante CPX2) a micropartículas magnéticas funcionalizadas com ácido 
nitrilotriacético, sendo o mesmo protocolo usado pelo grupo para citometria de fluxo. Um 
dispositivo de microfluídica que contém o elétrodo impresso foi especialmente 
desenvolvido para este trabalho, onde um campo magnético é gerado no elétrodo de 
trabalho para reter as partículas magnéticas, que foram previamente imobilizadas com 
o respetivo antigénio e anticorpos. Para obter volumes reprodutíveis, a suspensão que 
continha as partículas magnéticas foi propulsionada até ao elétrodo de trabalho através 
de uma válvula FIA, com a ajuda de uma bomba peristáltica. Os resultados obtidos são 
promissores, no entanto verifica-se alteração da superfície do elétrodo devido à 
adsorção inespecífica de proteína.  Atualmente, está-se a trabalhar no sentido de 
bloquear a superfície do elétrodo de forma a evitar adsorções inespecíficas e a avaliar 
formas de remover proteínas que possivelmente adsorvam. 
Em paralelo, exossomas foram isolados de plasmas de pacientes infetados com 
leishmaniose (sintomáticos, assintomáticos e curados). Estas vesículas são constituídas 
por proteínas antigénicas envolvidas na resposta imune contra o parasita e têm 
potencial para serem utilizados como novos biomarcadores da doença. Esta hipótese 
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foi verificada pela resposta das várias frações de material extracelular contra soros de 
cães e humanos infetados com leishmaniose. 
 
Palavras-chave: Leishmania infantum, Leishmaniose visceral, Reservatórios de 
doença, Cães, Casos assintomáticos, Imunossensores, Partículas micromagnéticas, 
Elétrodos impressos, Resposta potenciométrica, Vesículas extracelulares. 
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Abstract 
Leishmaniasis is a tropical neglected disease caused by the parasite Leishmania and it 
is transmitted to humans and dogs by the female Phlebotominae sandflies. The most 
severe form of the disease is visceral leishmaniasis that is fatal if left untreated. It is 
estimated that every year up to 30 000 people die. Due to several issues such as climatic 
changes and migration, the number of leishmaniasis cases has been rising. Another 
concerning issue is the lack of specificity in the current diagnosis methods, that lead to 
false results and unidentified infected dogs (asymptomatic cases) that can also 
contribute to the spreading of the disease. There is an urge to have an efficient and 
simple device to diagnose and screen dog serums, as they are natural disease reservoirs 
and therefore we want to control the silent spreading.  
In this project, we intend to create an immunosensor based in a well-known canine 
leishmaniasis biomarker by using screen-printed electrodes, as they are disposable, 
cheap, they respond quickly and they are easy to use. 
Electroanalytical techniques, as cyclic voltammetry and potentiometry, are currently in 
use to characterize the immunosensor.  The protocol used for the protein immobilization 
is based in the immobilization of the antigen through its histidine tail (currently the 
recombinant protein - CPX2) to magnetic microbeads functionalized with nitrilotriacetic 
acid, the same strategy used by the group in flow cytometry protocol. A flow device 
containing the screen-printed electrode was specifically developed for this work, where 
a magnetic field is generated in the working electrode for fixing the magnetic beads with 
the respective immobilization of the antigen and antibody. To allow reproducible 
volumes, the dispersion containing the magnetic beads is propelled to the working 
electrode by using flow injection analysis, with the help of a peristaltic bomb. When the 
samples go through the flow system, a magnet is activated which assures the magnetic 
microbeads fixation to the screen-printed electrode. The obtained results are promising; 
however, an alteration of the electrode surface is verified due to unspecific protein 
adsorption.  We are currently working to block the electrode surface to avoid unspecific 
adsorption and to evaluate the best approach to remove proteins that might adsorb. 
In parallel, exosomes (EXos) were isolated from plasma of infected patients 
leishmaniasis (symptomatic, asymptomatic and cured). These vesicles are constituted 
by antigenic proteins involved in the immune response against the parasite and might 
have potential as new disease diagnostic markers. This hypothesis was verified by the 
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response of several extracellular material fractions against leishmaniasis infected human 
and canine serums. 
 
Key words: Leishmania infantum; Visceral Leishmaniasis; Reservoirs; Dogs; 
Asymptomatic cases; Immunosensors; Micromagnetic beads; Screen-printed 
Electrodes; Potentiometric response; Extracellular vesicles. 
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Introduction 
1. Leishmaniasis - a neglected tropical disease 
Infectious diseases are the second cause of mortality around the world, according to the 
World Health Organization (WHO)1. Among the parasitic diseases, Leishmaniasis is the 
second cause of death after Malaria. This neglected tropical disease exhibits high 
morbidity and mortality putting at risk people from 98 different countries worldwide2. It is 
endemic in 88 countries and 1.8 million of new cases are estimated to occur each year3.  
Leishmaniasis is a vector-borne disease caused by the parasites Leishmania species 
and transmitted by the bite of infected female phlebotomine sandflies. Combining 30 
species of phlebotomine sandflies to more than 20 species of Leishmania species 
capable of causing disease, makes this opportunistic infection more complex to 
understand.4 
Several factors such as climate changes and changes in animal migratory movements 
have been contributing to the spread of this infectious disease5.  
Organism prevalence differs by geographical distribution, being an endemic disease in 
the tropics, subtropics and the Mediterranean basin6. The protozoan parasites of the 
genus Leishmania take advantage of the mammalian host to survive and affect 
predominantly least developed and emerging countries with limited resources and 
individuals with deficient immune system (for example, individuals infected with HIV – 
Human Immunodeficiency Virus)5,7. 
1.1 Pathological forms of the disease 
More than 20 Leishmania species are known to cause disease and the outcome of the 
infection will depend not only on the parasite species but also on the immune response 
of the host and the environment8. Different parasite species can cause identical 
pathology9.  
Leishmania species (spp.) lead to specific clinic-pathological categories: cutaneous 
Leishmaniasis, mucocutaneous Leishmaniasis and visceral Leishmaniasis, also known 
as kala-azar (Figure 1). Symptoms range from skin lesions to affecting cutaneous and 
mucosal tissues or even to vital visceral organs damage4,8. 
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1.1.1 Cutaneous Leishmaniasis 
Cutaneous Leishmaniasis (CL) is the most studied form of the disease. It is caused by 
L. tropica and develops as a nodule in the site of inoculation, consequence of the 
infection of macrophages in the dermis that may develop to a dermal granuloma, an ulcer 
that heals spontaneously or several inflamed ulcers that take longer to heal (a few 
months to years). Histologically it is characterized by a lymphoid and monocytic infiltrate 
with granuloma formation. L. mexicana and L. aethiopica are responsible for a particular 
kind of CL in which the nodules resemble to lepromatous leprosy8,9. 
1.1.2 Mucocutaneous Leishmaniasis 
This clinical presentation of Leishmaniasis is caused by L. braziliensis. Mucocutaneous 
Leishmaniasis (MCL) on the contrary of CL, which is confined to small areas of the skin, 
spreads to the oral and nasal mucosa and is characterized by disfigurative ulcers that 
take long time to heal. These progressively destructive ulcers, unlike cutaneous 
Leishmaniasis, are not self-healing and appear months or years after the first episode of 
CL4,10.  
1.1.3 Visceral Leishmaniasis 
Visceral Leishmaniasis (VL), also known as kala-azar, is the most severe form of 
Leishmaniasis and is fatal if left untreated6. Each year there are 500 000 new cases of 
VL, mainly in endemic areas (90% of these in India, Bangladesh, Brazil, Nepal and 
Sudan)11 (Figure 2). This disease strikes the most in poorest countries and can have a 
disastrous impact when it strikes a non-immune population.  
VL is caused by the Leishmania donovani complex, which includes L. donovani, L 
chagasi similar to L. infantum12.  
An incubation period (from 1 month to 2 years) is followed by clinical manifestations such 
as fever, splenomegaly, hepatomegaly, weight loss, progressive anemia, pancytopenia. 
These typical symptoms of this systemic infection are characteristics of the dissemination 
CutaneousMucocutaneousVisceral
Figure 1 - Pathological forms of leishmaniasis – visceral, mucocutaneous and cutaneous109. 
FCUP 
Development of an innovative immunosensor for Leishmaniasis screening 
3 
 
of parasites throughout the blood and reticuloendothelial system which lead to enlarged 
lymph nodes, spleen and liver8. 
Post kala-azar dermal Leishmaniasis is considered a sequel of VL in which skin is the 
focus of infection and appears like a nodular rash. This condition is frequent in Sudan 
and in the Indian subcontinent13. 
As an opportunistic infection, the parasite prevails in people whose immune system has 
been compromised. Thus, coinfection is common among HIV patients in Mediterranean 
countries, Brazil, east Africa and the Indian subcontinent14. 
 
Figure 2 - Distribution of Endemic Visceral Leishmaniasis worldwide 2015. World Health Organization15.  
1.2 Epidemiology 
Leishmania spp. capable of causing disease are divided in two main groups: Old world 
species (L. major, L. tropica, L. aethiopica, L. donovani, L. infantum) and New World 
species (L. mexicana, L. amazonensis, L. brasiliensis, L. guyanensis, L. chagasi).8 
Visceral Leishmaniasis (VL) is caused by L. donovani (East Africa and the Indian 
subcontinent) and L. infantum (Europe, North Africa) in the Old World and L. chagasi in 
the New World (Brazil). While L. donovani infects all age groups, L. infantum infects 
mostly children and immunosuppressed individuals. Among other regions, L. infantum is 
responsible for VL in children in the Mediterranean basin. However, due to increasing 
prevalence of human immunodeficiency virus (HIV) infection in this region, HIV-VL 
coinfection in the adult population is being reported frequently. L. chagasi similar to L. 
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infantum causes VL in children in Latin America, where lymphadenopathy is a dominant 
clinical feature16.  
Due to urbanization and HIV pandemic, the incidence of VL is rising. More than 350 
million people live in active parasite transmission areas, putting their health at risk17. 
Furthermore, each year there are up to 30 000 deaths due to this severe form of the 
disease9. 
This disease affects mostly least developed countries and poorest regions, where 
malnutrition, displacement, poor housing, weak immune system and lack of resources 
are common issues. Although not fully recognized, socioeconomics subjects are tightly 
connected to poverty and endemicity of this disease9.  
1.3 Transmission 
1.3.1 Leishmania life cycle 
Sandflies used to be limited to their natural distribution areas but, as previously 
mentioned, several causes (migration, climate changes, economic development, etc.) 
lead to the spread of sandflies as well as Leishmania reservoirs and consequently lead 
to the disease incidence.  
There are more than 800 known species of phlebotomine sandflies but only certain 
species of sandfly of the genus Phlebotomus (Old World) or Lutzomyia (New World) 
transmit the Leishmania spp. parasites11. 
 
Figure 3 - Leishmania spp. life cycle. Ref 168 © (2001) American Society for Microbiology 4. 
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The parasites have a digenetic life cycle that includes an extracellular developmental 
stage in the female phlebotomine sandfly and another one in the vertebrate host, mostly 
intracellular. The parasite development in sandflies occurs in the alimentary tract, where 
promastigotes (the motile, flagellated, extracellular form of the parasites) are formed. 
Maturation of the parasite occurs in the midgut, where it develops to the infectious 
development form of the parasite: metacyclic promastigotes. 
The transmission of the parasites to the mammalian host occurs during insect blood 
feeding. Usually, an inoculum contains around 100–1000 metacyclic promastigotes that 
are rapidly engulfed by mono and polymorphonuclear cells. Within these cells, the 
parasites go through other morphological changes, differentiating to an ovoid shape with 
short flagellum known as amastigote. Once they take this form, they multiply and the 
cycle becomes complete when the sandfly takes another blood meal with the 
amastigotes18,19 (Figure 3). 
1.3.2 Transmission Pattern  
There are two types of VL transmission: zoonotic, when the disease can be transmitted 
from animal to vector to human, and anthroponotic is transmitted from human to vector 
to human. Transmission characteristics also differ according to geographical regions, 
being L. donovani responsible for the anthroponotic transmission and L. infantum for the 
zoonotic transmission. Anthroponotic transmission occurs in the Indian subcontinent and 
the zoonotic type is mainly transmitted in the Mediterranean basin and South America 
regions. 
1.3.2.1 Zoonotic disease 
Zoonotic visceral Leishmaniasis is a serious public health problem that affects some 
mammals and results in significant mortality and morbidity where it is endemic20.  Animals 
such as wild canid, marsupials and rodents have been described as reservoirs of human 
VL21. However, zoonotic VL epidemics have been associated only in areas where canine 
Leishmaniasis is endemic. 
Canine visceral Leishmaniasis (CVL) is caused by Leishmania infantum in the 
Mediterranean area, Middle East and Asian countries and is caused by Leishmania 
chagasi in Latin America. Due to their genotypic relationships, these two species are 
considered identical22.  
1.3.2.1.1 Dogs as main reservoirs 
Although dogs are recognized as the main source of infection, the current control 
diagnosis methods and treatment are directed to humans23. 
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In fact, from an epidemiological point of view, canine visceral Leishmaniasis is more 
important than Leishmaniasis affecting humans since its incidence is higher and both 
symptomatic and asymptomatic dogs are infectious to sandflies24. Besides, CVL is a 
veterinary issue because in endemic areas such as the Mediterranean Basin and Brazil, 
domestic dogs are the primary source of infection by the vector, allowing its life cycle 
perpetuation. 
After an incubation period that can range from three months to several years, dogs might 
start presenting some clinical signs. Nevertheless, some dogs remain asymptomatic and 
never develop clinical signs11. 
Thus, dogs can present different forms of the disease: symptomatic, oligosymptomatic 
and asymptomatic. It is of great relevance mentioning that all forms of the disease enable 
the transmission of the parasite. 
Symptomatic CVL typically results in death and it is based on the presence of at least 
two clinical manifestations. Infected dogs present cutaneous alterations such as 
alopecia, onychogryposis, dermatitis, skin ulceration and visceral manifestations with 
splenic, renal, hepatic, and neurological disorders. Other symptoms as anorexia and 
weight loss are also usual25. Infected dogs can remain asymptomatic, not presenting 
detectable clinical signs of disease. This is a grave problem, since these animals can 
contribute to the maintenance of Leishmania cycle24. Dogs that develop a few mild 
symptoms are classified as oligosymptomatic. 
Despite evidences showing that killing seropositive animals leads to a decrease 
incidence in CVL and VL in children, this control method is not well accepted26.  
However, due to lack of accuracy in diagnosis methods the number of detected infected 
dogs cannot be elucidative of the real prevalence of infection. The number of infected 
dogs are estimated in few millions but it is believed that the real burden of disease is 
much higher23.  
We would expect that seroprevalence of CVL was higher in rural areas, where the 
sandflies are mainly found but the fact that there are more hosts infected in urban areas 
leads to the increase of CVL and higher prevalence when compared to rural areas. 
Unlike expected, urban areas favor the transmission of parasite due to high number of 
dogs and gardens. It provides a good environment to sandflies proliferation27.  
A sensitive and specific method to detect canine Leishmaniasis in early stages is needed 
to avoid false positives and false negatives that lead to unnecessary euthanasia and 
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disease transmission, respectively11. Detection of asymptomatic dogs is critical for 
controlling the spread of the disease among dogs and between dogs and humans. 
The foundation to an effective control is prevention, screening and detection of the 
disease, since treating infected dogs is not that effective (relapses occur frequently and 
they can regain infectivity weeks after treatment)28. Besides, VL drugs might lead to 
parasite resistance.  
2. Prevention and treatment 
One approach to control the infection is doing vector control. This can be achieved with 
insecticides, such as pyrethroids and DDT. However, sandflies may develop resistance 
to DDT but remain sensitive to other insecticides. Bed nets and spraying are also 
alternative options to minimize the contact of some species with the host. Nevertheless, 
consequences concerning sandflies populations resistance are still under study29,30. 
Regarding dog protection, collars impregnate with deltamethrine reduce the risk of 
infection in dogs. 
Few drugs are available for the treatment of Leishmaniasis and besides the risk of 
developing drug resistance, treatment efficacy depends on strains and species9. 
Furthermore, there is no Leishmaniasis human vaccine available. Vaccination would be 
a good option to prevent infection31.  
 Vaccination of dogs would still be the best strategy if an efficient vaccine was developed. 
Being lauched in Portugal in 2011, CaniLeish® was the first vaccine for canine 
Leishmaniasis in the European Union. In Brazil, LeishTec® vaccine was also registered 
but only about 40% of protection against infection was found. Despite the efforts, 
Leishmania vaccinology still has a lot to improve till an effective and universal vaccine is 
developed32. 
3. Screening, detection and surveillance  
Monitoring and controlling the spread of emerging diseases is a topic that should concern 
all individuals.  
Disease surveillance is a crucial component to eliminate or at least to minimize the 
spreading of this infectious disease before the burden is devastating33. 
The first step to treat a condition or to take preventive measures is to diagnose. Taking 
appropriate actions will lead to improved health outcome. However, to achieve proper 
and accurate diagnosis a robust, rapid diagnosis test is needed5. Once we have a 
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diagnosis test with these characteristics efficient clinical and epidemiological 
management of infections can be made34. 
There is an urge to develop a tool both sensitive and specific that allows an easy 
screening in endemic regions, capable of identifying asymptomatic cases35. This 
diagnosis method should also be accessible, providing the possibility of doing periodic 
monitorization. 
The process to diagnose should be automated, requiring inexpensive reagents and 
minimal operator intervention without diminishing the fidelity of the results. Considering 
that this disease affects mostly less developed countries the tests should be cheap and 
easy to perform in difficult field conditions5,36. 
4. Diagnosis methodologies 
Accurate diagnosis still remains a problem to disease control since leishmaniasis 
presents a wide range of manifestations37. Clinical manifestations can also be confused 
with other illnesses often common in Leishmania endemic areas such as malaria, 
toxoplamosis and tuberculosis38. 
Many Leishmaniasis noninvasive diagnosis are available but none has both specificity 
and sensitivity to diagnose in endemic areas. We must have into account that age, 
medical history and host immune system response are crucial parameters in diagnosis.  
According to WHO, diagnosis of Leishmaniasis can be confirmed with more conventional 
laboratorial techniques such as visualization of parasite in tissues by microscopic 
examination of the stained specimen or in vitro culture of the parasite from biopsies or 
aspirates from lesions, lymph nodes, spleen and bone marrow and other diagnosis 
methods that include molecular detection of parasite DNA in tissue samples and 
serological tests that detect anti-Leishmania antibodies9. 
4.1 Parasitological diagnosis 
Parasitological diagnosis of Leishmaniasis is specific and remains the gold standard to 
diagnose this infectious disease39. 
One of the reference standards for diagnosis is the demonstration of parasites in tissue 
samples from bone marrow, skin lesions, liver, lymph nodes and spleen. Diagnostic is 
obtained by observation of the Leishmania amastigote forms in stained microscopic 
preparations with Giemsa6. 
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The best results are obtained with spleen aspirates (93%-98% of sensitivity). When it 
comes to bone marrow aspirates, the sensitivity decreases to 60%-85% and worse 
results are obtained with lymph nodes aspirates (sensitivity ranges between 52% to 
58%)4. 
Besides this method requiring trained personnel and its sensitivity being variable, it 
involves invasive sampling being a risky procedure that can lead to fatal hemorrhage so 
it must be carried out in settings with access to surgical facilities. Lymph node and bone 
marrow aspirates are safer but the material obtained is more diluted and therefore less 
sensitive, raising the risk of diagnosing false negatives40. 
The culture of parasite from infected tissues is another classical confirmatory test for VL. 
A major problem with this technique is that different species of Leishmania have different 
growth factors and contaminations are recurrent. Despite being more sensitive than 
microscopic examination, it is time consuming and expensive, so it is rarely used for 
clinical diagnosis12.  
Identification of amastigotes by direct examination of aspirates must be done by experts 
because the results are dependent on the observer9. It can also harvest false negative 
results because of the low number of parasites in some samples, particularly in 
asymptomatic cases, where the parasite charge is lower.  
4.2 Serological diagnosis 
Serological tests are based on the screening of antigens or antibodies.  
The first approach is an excellent method to diagnose an infection since is more specific 
that antibody-based immunodiagnostic tests. Thus, antigen levels are expected to 
correlate with parasite charge, and this method might be useful when antibody prediction 
is deficient. Besides, this approach should avoid cross-reactivity and should distinguish 
active from past infections.6 However, this technique is still unreliable at the moment 
(lack of specificity and variable sensitivity), so efforts are being made to improve this tool, 
as it stands as a promising approach. 
Currently, most clinical and surveillance laboratories of the developing world use 
serological techniques to detect pathogen-specific antibodies, since direct methods are 
either invasive and potentially fatal or expensive. 
VL infection is characterized by the presence of humoral response that leads to the 
production of antibodies specifically against to Leishmania spp.. Thus, serological 
methods to detect anti-Leishmania antibodies are useful as alternative diagnosis tests 
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for both human and canine Leishmania infections27. They have the advantage of being 
easily applied to a large amount of samples with specificity and sensitivity, mostly used 
in seroepidemiological studies41. 
The presence of anti-Leishmania antibodies in both asymptomatic and symptomatic 
infected dogs has allowed the development of agglutination tests, immunofluorescent 
serologic tests, such as Western blotting, immunochromatographic tests, and enzyme-
linked immunosorbent assays (ELISAs).  
The sensitivity depends on the methodology but the specificity will always depend on the 
antigen used. In most serological tests, the sensitivity and specificity data are compared 
against the standard methodology 16.  
Serological tests are the elected to diagnose CVL. Nevertheless, when dogs present low 
antibody titers these tests lack sensitivity and specificity. Is not unusual to occur cross-
reactivity too42. Moreover, after a successful treatment, it takes a while till antibody levels 
decrease so it can mask a relapse, making impossible to diagnose it. 
4.2.1 Direct Agglutination Test 
As an attempt to substitute the risky procedure of splenic aspirates, a noninvasive 
serological test was developed. Direct agglutination test (DAT) was the first antibody 
detection test used for VL diagnosis and has been used for more than 25 years. 
DAT is a simple semi-quantitative diagnostic tool used in many developing countries with 
a high sensitivity (91-100%), specificity (72-100%), accuracy, reliability and 
inexpensiveness4,43.  
DAT detects parasite antibodies in the blood or serum of those infected through direct 
agglutination. Whole Coomassie-stained promastigotes, either in a suspension or in 
freeze-dried form are incubated with serial dilutions of serum. If the result is negative 
(absence of anti-Leishmania antibodies) DAT antigen accumulates at the bottom of the 
plate. If there are anti-Leishmania antibodies present, the antigens form a film over the 
well (positive result). In a positive reaction, agglutination can take till 18 hours of 
incubation to occur9,41. 
The disadvantages of DAT are requiring moderate technical expertise (the interpretation 
of the results depends on the person analyzing the results, creating inter-observer 
discrepancy)44, serial dilutions must be done (requires a considerable volume of antigen) 
and relatively long incubation time43,45.  
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DAT results remain positive long after the patient is cured (anti-Leishmania antibodies 
can persist for years as a result of a VL infection), so this test is not appropriate to detect 
relapses6. 
4.2.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA is an important serodiagnosis technique used in almost all infectious diseases, 
including VL.  
These ELISA assays are based on the detection of antibodies present in the blood or 
serums. An antigen/recombinant protein is used to coat the plate and then the samples 
containing antibodies are incubated. To see the development of signal, a secondary 
antibody conjugated to an enzyme recognizes and binds to the primary antibody. After 
adding a substrate, a colorful product is developed and the results can be measured by 
optical density techniques. 
This tool is frequently used to detect anti-Leishmania antibodies due to its high sensitive 
and specificity as well as good reproducibility and high throughput screening of large 
number of samples at affordable expenses. However, the specificity of this technique 
depends on the antigen used.  
The sensitivity of crude soluble antigens (CSA) in an ELISA is high. Nevertheless, cross-
reactions with serum from patients with trypanosomiasis, toxoplasmosis and tuberculosis 
can occur. VL diagnosed by ELISAs is based on crude soluble Leishmania antigens 
(SLAs).  Though its high sensitivity, the specificity is low due to the antigens related with 
Leishmania and other pathogenic protozoa. It also has low competence to detect 
seropositivity in asymptomatic dogs27,45,46. 
ELISA’s major disadvantage is its inadaptability for field conditions in resource-poor 
settings and its requirement for specialized operators. 
4.2.3 Indirect Fluorescent Antibody Technique (IFAT) 
Fluorescent antibody techniques are extremely valuable tools that allow evaluation of 
anti-Leishmania antibody titers produced by infected individuals. It is a quite useful 
method in epidemiological studies and in clinical practice47.  
IFAT is based on the use of fluorophores to detect antibodies present in the sample. It 
involves the use of a primary antibody to bind to the antigen and allow the formation of 
antigen-antibody complex and posteriorly the binding of a fluorophore-conjugated 
secondary antibody that results in an amplified signal that can be examined by 
fluorescence microscopy. 
12 FCUP 
Development of an innovative immunosensor for Leishmaniasis screening 
IFAT is the serological gold standard for the diagnosis of CVL in most countries around 
the Mediterranean basin. This methodology is different from ELISA and it resorts to the 
whole body parasite as antigen47. Although high specificity and sensitivity (100% and 
90%, respectively), IFAT sensitivity is lower for asymptomatic infections when compared 
to ELISA. Also, the result interpretation depends on operator’s expertise46,48. 
4.2.4 Immunochromatographic tests 
Immunochromatografic (IC) tests are a great option to be used in large-scale surveys, in 
which antibody titers are not required. The results are always evaluated considering the 
epidemiological context of the area and the aim of the investigation49. 
IC test principal is similar to the one used in ELISA but the main difference is that the 
reaction occurs in chromatographic paper by capillary action. Immunochromatographic 
tests are based in the formation of an antigen-antibody complex. Then, the sample 
migrates in the membrane and the labelled antibody gets in contact with the immobilized 
antibody in the membrane and it results in the formation of color. The appearance of 
color is indicator of the antigen presence in the sample. 
IC tests are inexpensive, practical, rapid and suitable for field use. However, in 
resemblance to DAT, a significant portion of healthy individuals is diagnosed as positives 
in endemic regions after long cure period (false positive cases). So, patients with suspect 
of relapse are not candidates for diagnosis49. 
4.2.5 Flow cytometry 
Flow cytometry (FC) is considered an emerging technology for the diagnostic of several 
infectious diseases. It usually refers to the measurement of cells but the approach of 
making optical measurements in a flowing sample stream is a general analytical 
approach50. 
Flow cytometry is a technique based on the analysis and sorting of cells or particle 
suspensions in a controlled fluid stream through the measurement of fluorescence and 
scatter induced illumination. Using specific fluorescent markers, flow cytometry can be 
used to the quantification of structural and functional parameters on a single-particle 
basis. 
Flow cytometry technique can quantify specifically the antibodies against Leishmania 
surface antigens, restraining potential cross-reactivity against more conserved 
intracellular structures. All the approaches to date used live or fixed promastigotes as 
targets to detect specific antibodies51.  
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Among others, flow cytometry has high throughput capacity, possibility of quantification, 
high reproducibility and sensitivity and potential for multiplexing52.  
Recently, alternative methodologies were proposed to improve the serological 
approaches. One of them is immunoglobulin G (IgG) flow cytometry to detect anti-
Leishmania braziliensis antibodies in sera of active cutaneous Leishmaniasis patients 38. 
This method has shown to be reliable, achieving high levels of sensitivity and 
specificity51. Studies have shown the FC potential to monitor postchemotherapy cure of 
VL, in order to evaluate the success of treatment. The antibodies which are detected in 
FC are the anti-membrane-specific antibodies and are only present during active disease 
which makes it a perfect technique to evaluate the effectiveness of the treatment53.  
4.3 Detection of parasite DNA 
Polymerase chain reaction (PCR) technology has become an indispensable tool for the 
diagnosis of many parasitic diseases, including Leishmaniasis. Amplification-based 
methods include the conventional PCR (polymerase chain reaction) and qPCR 
(quantitative polymerase chain reaction)54.  
PCR is based on the amplification of specific parasitic DNA sequences. The sensitivity 
of a PCR assay depends upon three factors: the physicochemical conditions of the 
reaction, the concentration of the DNA target and the selected PCR primers20,55,56. It has 
higher sensitivity for asymptomatic animals and early-stage infections when compared 
to serological methods.  In patients with compromised immune system, PCR is also more 
sensitive than the classical parasitological methods.  
Some PCR drawbacks are collection of samples, storage conditions and difficult access 
to sophisticated equipment57. Lack of standardization in the selection of target 
Leishmania DNA sequences and experimental protocols used worldwide also makes it 
harder to compare the sensitivity and specificity of these tests.  
Real-time quantitative PCR (qrtPCR) is an innovative technology that has revolutionized 
molecular diagnostics by adding sensitivity, speed, broad dynamic range of target DNA 
quantification and reduced contamination. When compared with conventional PCR, it 
has the major disadvantage of costing three times more55,58. 
As we have seen above, every technique has its downsides.  
Parasite demonstration in tissue smears and culture provide definitive diagnosis of VL, 
but generally has lower sensitivity than serologic methods. Particularly, splenic aspirate 
has the highest sensitivity of available tissue sampling techniques, but it has a risk 
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associated.  Moreover, microscopy techniques lack sensitivity, whereas culture requires 
long time to obtain a result and is vulnerable to contamination59. 
Molecular diagnostic tools like PCR and real-time PCR are quite sensitive and specific 
but are difficult to perform and have a high cost.6 So, its use  remains largely restricted 
to some hospitals and research centers37.  
Serological tests are often not sensitive enough to detect asymptomatic individuals so 
they have to be combined with classical methods of diagnosis to confirm. ELISA, IFAT, 
DAT and rK39 immunochromatographic strip test (ICT) are highly sensitive and specific 
when analyzing active VL in immunocompetent individuals. This doesn’t happen when 
titers decline and parasite charge is lower. Due to these reasons, tests give false-
negative results frequently in immunocompromised patients and for asymptomatic 
Leishmania infections60. 
For those reasons, it is crucial to identify and produce new proteins capable of detecting 
asymptomatic Leishmaniasis and individuals in early stages of infection in VL endemic 
regions. 
5. Recombinant proteins and novel biomarkers 
Every diagnosis platform has its detection limits and sensitivity but these factors are also 
dependent on the specificity of proteins for producing high confidence results with lower 
detection limits. There is an urge to develop a marker for the active diseases6.  
Antigens related to the disease are discovered and validated through genomics and 
proteomics research. The development of new technology to diagnose can enable rapid 
introduction of these new antigens into clinical practice36. This tool must provide a signal 
of presence or absence of a particular antibody but also provide quantitative 
information36.  
The main problem with Leishmaniasis diagnosis is identification of markers that can 
detect the presence of disease since early stages until recovery after treatment. 
Seroconversion does not happen right after infection so serological tests may lead to 
false-negative results. New recombinant antigens are needed to contribute for a more 
accurate Leishmaniasis diagnosis and hard work has to be put in the development of a 
more sensitive and specific recombinant protein-based immunoassay capable of 
detecting asymptomatic cases in large screening studies61,56.  
Recently, several Leishmania spp. proteins were cloned, purified, and characterized to 
improve the diagnosis of Leishmaniasis62,63. The major advantages of using recombinant 
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proteins for the diagnosis of Leishmaniasis infections are: knowing the precise antigenic 
composition applied to the serological tests; good reproducibility and easy method 
standardization23,64,51,63. 
Using recombinant polypeptides containing specific L. donovani / L. chagasi epitopes 
that elicits an immune response in the majority of dogs and humans with VL can 
overcome some cross-reactivity problems11. Moreover, the variability in the humoral 
response concerning different parasite antigens observed in infected dogs suggests that 
a combination of recombinant proteins can improve the diagnosis efficiency65.  
Different families of proteins like kinesin-related proteins, heat shock proteins, nuclear 
proteins, ribosomal proteins, enzymes and other antigens were evaluated regarding their 
performance (sensitivity and specificity) of immunological diagnosis40. 
Recombinant protein rK39 (39-amino acid repeat of a kinesin-related protein), highly 
conserved in Leishmania spp., is a great tool to the diagnosis of VL in HIV patients and 
a prognostic indicator for monitoring patients undergoing drug treatment64,59,61. An 
important aspect of anti-rK39 antibody is that the titer correlates directly with the disease 
activity, indicating its potential for use in predicting response to therapy16. Among the 
recombinant antigens, this one showed promising diagnosis and has been extensively 
tested in the last 5 years with IC tests in several Leishmaniasis endemic areas4,6, with 
several commercial applications (Appendix 1). rk39 has also been tested for  ELISA  and 
FC assays showing high sensitivity and specificity in detecting clinical forms of CVL52. 
However, rK39 doesn’t have the same accuracy in asymptomatic cases with proven 
infection. Several proteins such as Leishmania infantum cytosolic tryparedoxin 
peroxidase (LicTXNPx, also known as CPX), a member of enzymatic Leishmania 
cascades for detoxification of peroxides expressed in all stages of parasite development, 
and rK28 (a synthetic gene generated by fusing multiple tandem repeats of haspb1 and 
k39 genes) were already described as valuable tools for the detection of infection6,23. 
LicTXNPx antigen has a highly immunogenic probe during both human and canine 
infections. Previous studies indicated that anti-LicTXNPx antibodies were present in both 
symptomatic and asymptomatic experimental canine infections, making this antigen a 
good candidate marker and a prognostic indicator for monitoring the response to VL 
treatment64.  
When testing rk39 and LicTXNPx in ELISA, rK39 demonstrated a better performance in 
the symptomatic group23 whereas LicTXNPx showed a better performance in the 
detection of infections in asymptomatic infected dogs.   An ELISA with both LicTXNPx 
and rk39 antigens (LAM-ELISA) was performed and both symptomatic and 
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asymptomatic dogs had higher specificity (96.3%). LAM-ELISA is a simple and sensitive 
(87.1% sensitivity) test that associated with DAT may be a valuable tool for screening 
CVL23,27.  
Attention to extracellular vesicles (EVs) has been rising in the last years as they are 
believed to be potential biomarkers to use in the diagnosis of diseases66. Our group has 
been working with EVs as we are interested in the proteic material contained in 
exosomes and its great clinical impact potential in nanomedicine67. This type of vesicles 
is naturally released from cells and its context of infection is not still very clear68. 
Particularly, the exoproteome of L. infantum is composed by two main fractions:  the 
vesicle fraction and the free protein fraction. It is believed that extracellular proteins 
derived from the parasite have an active role in host-parasite interaction69. This is an 
indicator that EVs can be used as future markers for infectious diseases. 
6.  Biosensors 
A major obstacle in defining prevalence and incidence of infection is the lack of an easy 
and accurate tool for the detection of infected individuals35.  
Since many infectious diseases spread quickly before any symptoms are identified, the 
diagnosis device must be a sensitive analytical tool that can easily go down to very low 
detection levels of antibodies without losing selectivity.  Biosensors meet these field 
requirements as they are simple, cheap, robust, accurate, rapid and provide high-
throughput33. Even more, they offer the possibility of real-time monitoring, and the 
distribution of these diagnosis tools in the field provide a rapid infection detection33 of the 
disease that has a significant effect on the success of disease spreading, control, or 
eradication5.  
A biosensor is a sensing device containing a bio-recognition element that interacts with 
a biomarker and a transducer that converts the changes in its physicochemical properties 
(optical, thermal, electrical, and thermodynamic properties) into an electrical signal 
(Figure 4). The biosensors can be classified based on the type of bio-recognition element 
or the transducing method used5.  Based on the bio-recognition element, the biosensors 
can be classified as enzyme sensors, immunosensors, nucleic acid probe (DNA and 
RNA) sensors, or cell-, tissue-, or organelle-based sensors70. Based on the transducing 
method, biosensors can be classified as piezoelectric, optical, or electrochemical 
biosensors5. 
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Figure 4 - Schematic diagram of biosensor elements: target analyte; bioreceptor; transducer. Image adapted from “The 
role of biosensors in the detection of emerging infectious diseases”, 2006 33 
There are several factors that affect the efficacy of the biosensor. Thus, all characteristics 
that influence the accuracy of these biosensors (biomarker/bio-recognition element 
ligation, surface preparation/immobilization conditions, incubation time, temperature, 
etc.) have to be optimized during the development process. 
One of the major problems with biosensor are matrix interference and adsorption of blood 
components onto the sensor surface. Furthermore, biosensors have to be robust and 
work outside laboratories to be applied to real-time detection of infectious diseases in 
biological samples (i.e., blood)33.  
As we intend to develop a biosensor to detect an infectious disease and the host immune 
response to the parasite involves a humoral response and the development of antibodies 
against it, we decided to focus our attention on immunosensors in this revision. 
6.1 Immunosensors 
Antibody-based sensors, also known as immunosensors, are well accepted due to the 
specificity of antibody-antigen reaction to produce a change in the transducer signal5. 
They are considered more versatile than enzyme-based biosensors, because the 
antigens can be produced specifically to any biomolecule of interest71. These biosensors 
are ideal as they rely on the high affinity between the antibodies and the antigens 
(recognition element), resulting in very low detection limits72,73, with less level of 
interferences, non-destructive approach to sample, stability, good precision and high 
sensitivity74. These devices should be compact and allow simple operation75.  
The disadvantage of these immunosensors is that the antigen is not easily released from 
the antibody after the measurement has been made. Thus, several strategies have been 
applied to design inexpensive biosensors71. Another option involves the use of a flow cell 
configuration in which the immunochemicals can be partially removed from the sensor 
before the next measurement71.  
Independently of the biosensor’s type, immobilization of the bioreceptor onto a solid 
support is a crucial aspect in determining the overall performance of the device33.  
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To obtain a diagnosis device with the characteristics mentioned above, we have to 
overcome some drawbacks regarding sensitivity, stability and longevity that mostly 
depend on the amount of the immobilized immune molecules on the surface, their 
conformational stability, remaining activity after the immobilization procedure and their 
orientation on the sensor surface74. The last is particularly important since 
immunoglobulins are asymmetrical molecules and wrong immobilization can lead to 
hindered interaction with the biomarker. Highly controlled orientation immobilizations are 
preferable to maximize their antigen-binding efficiency and achieve the best 
immunoassay sensitivity and selectivity. Oriented binding may require many chemical 
modifications that decrease the control over the nanostructures76.  
There are three main methods of immobilization: adsorption, entrapment and covalent 
binding. 
Adsorption is a rapid and simple procedure, especially for disposable biosensors. This 
physical type of immobilization is based on Van der Waals attraction between 
biomolecule and the solid support surface. The most relevant drawbacks of this 
technique are that bonding forces between biomolecule and support are weak and an 
even monolayer cannot be guaranteed. As a consequence, the biological component 
can be leached during the assay, depending on experimental conditions such as pH, 
ionic strength, temperature and solvent71.  
Electropolymerization is an easy and attractive example of the entrapment technique. A 
biological molecule is homogenized in a monomer matrix and this is then deposited by 
electropolymerization71.  
Immobilization cross-linking, or covalent immobilization, is used to coat electrode 
surfaces with specific biotransducer molecules. Covalent immobilization of the 
biorecognition component (enzyme, antibody, cell, etc.) can be achieved by use of the 
self-assembled monolayer (SAM) procedure71. The method is based on the formation of 
three-dimensional links between the biological material and multifunctional reagents. 
Antibodies can be directly immobilized on the surface of the transducer by covalent 
bonding through amino, carboxyl, or aldehyde groups5. This technique has several 
advantages, such as stability and reusability of immunosensors due to covalent bonds74. 
Several immunosensor technologies advances have been made in the last years, with 
distinct notability to transducer approaches and their clinical potential such as for the 
detection of Salmonella pullorum77, hepatitis B77,78 and dengue79. 
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Specifically for Leishmania spp., some developments have been made. A biosensor for 
Leishmaniasis had already been developed, in which proteolipossomes from mice were 
immobilized in interdigitated electrodes80. The concentration of antibodies anti-L. 
amazonensis was detected by EIS down to a concentration of 10-5 mg/mL. However, this 
specie of Leishmania has its clinical manifestations as cutaneous and mucocutaneous 
Leishmaniasis80. A piezoelectric immunosensor for detecting L. chagasi antibodies from 
canine serums was developed81. This immunosensor was capable of detecting antigen 
concentrations up to 3 µg/mL and to recognize antibodies anti-L. chagasi in canine 
positive serums up to 1:3200 dilution resorting to a quartz crystal microbalance81. Also 
capable of detecting canine serums antibodies of L. infantum, a surface plasmon 
resonance based immunosensor was successfully constructed detecting antibodies up 
to 1:6400 dilution82.  
Even though the two previous techniques had good results they were only tested for a 
limited number of positive samples of infected Leishmaniasis canine from endemic areas 
and for non-infected dogs. Nevertheless, asymptomatic canine serums remained to be 
studied. The lack of further study in this type of samples and the fact that electroanalytical 
immunosensors are taking an important place in the detection of infectious diseases 
gave us the opportunity to do experiments and to construct an immunosensor that meets 
the needs of diagnosis. Due their potential and their progress in the last few years it was 
decided to use electroanalytical techniques as the preferential approaches to construct 
the canine leishmaniasis immunosensor.  
6.2 Electro analytical biosensors 
More than half of the biosensors used for the detection of pathogens are based on electro 
analytical methods. They can be classified as amperometric, impedimetric, 
potentiometric and conductometric methods based on the electrical parameters they 
measure.  
They constitute, possibly, the most practical and quantifiable of all low-cost diagnostic 
assessments of protein presence. Electroanalytical methods provide accurate and rapid 
response times, they are easy to use, efficient, portable, and low cost. Electrochemical 
detection also offers selectivity, as different electroactive molecules can be 
oxidized/reduced at different potentials. Additionally, this technique is compatible with 
miniaturization methods, has minimal power requirements and is independent of sample 
turbidity and color83. Thus, it allows a rapid, permanent control and a direct transduction 
of the biomolecular recognition event into electronic signals71,84. 
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6.2.1 Amperometric biosensors 
Amperometric biosensors transduce biological recognition events caused by 
oxidation/reduction of the electroactive species into an electrical current (typically, in the 
nanoampere to microampere range) to quantify an analyte within a sample matrix5. 
Amperometric transducers are used to study the charge transfer between the interfaces 
of phases. One of the half-cell reactions within the electrochemical cell is carefully 
controlled to study the changes in charge transfer at the interface of the other half-cell 
reaction, known as the working electrode. On formation of the overpotential, electron 
transfers occur and oxidative or reductive reactions follow. These processes are known 
as Faradaic processes. Other processes as the development of a layer, change the 
interfacial surface but do not cause charge transfer across the interfacial boundary, are 
termed non-Faradaic processes85.  
The aspects that influence the reaction rate are: concentration of the analyte and other 
species within the matrix at the interface; mass transport of species from bulk solution to 
the interfacial boundary; electron transfer across the interfacial boundary; electrode 
interactions such as adsorption and electrodeposition; and external factor like 
temperature. 
In voltammetric methods, the potential applied to the electrode-solution interface 
changes as a function of time, together with the measurement of the current. Cyclic 
sweep voltammetry is often the chosen method for information acquisition such as 
oxidation/reduction potential, kinetics, and reaction mechanisms (Figure 5). Among all 
the electrochemical characterization methods, pulse strategies such as Square Wave 
Voltammetry (SWV) are possibly the most sensitive and the most used in electro 
analysis. The main advantage of pulse techniques resides in the different decay rates of 
the charging and faradaic currents. Charging current decays more rapidly compared to 
the faradaic current, during each pulse, so the capacitive current is negligible, allowing 
lower detection limits. Numerous studies relate detection of pathogens and the use of 
SWV86. 
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Figure 5 - Representative voltammogram resulting of a cyclic voltammetry 
6.2.2 Impedance biosensors 
Impedance spectroscopy is another electrochemical method that has also interest for the 
detection of infectious diseases.  
To simplify, the real part of impedance is linked to resistive processes and the imaginary 
part to capacitive processes. In Nyquist plots, the charge transfer resistance (Rct) of 
impedimetric biosensors can be measured based on the calculation of the diameter of 
the semi-circle of the real part of impedance87 (Figure 6). Rct represents the electrostatic 
and/or steric barrier presented to the redox probe at the surface as the films are being 
constructed79. As the sensing layer is being designed and layer-by-layer assembly 
processes on to a sensor surface occur, the Rct increases79.  
 
Figure 6 - EIS Nyquist plot (Zimag against Zreal). Image adapted from “Electrochemical biosensors and nanobiosensors”, 
2016, Portland Press Limited 85 
Electrochemical impedance spectroscopy (EIS) is subdivided in two main categories: 
Faradaic and non-Faradaic. In the Faradaic measurements, redox probes are applied in 
the experiment and the analysis is based on charge transfer resistance changes 
generated by the blocking presence of the analyte when it binds to the surface. In non-
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Faradaic EIS exploits charging currents; redox probes are not used and double layer 
capacitance changes upon target binding is the main method of analysis85.  
Impedance detection involves measuring the change in impedance (combined 
measurements of the charge transfer resistance and interfacial capacitance) caused by 
the binding of biomolecules to receptors (antibodies, DNA, proteins, etc.) immobilized on 
the surface of electrodes. Changes in the surface properties can be linked to the 
biochemical changes33.  EIS is a direct method for probing classical antigen–antibody 
binding events with good sensitivity and reproducibility79,88,89. 
During the last decade, the number of EIS applications in biosensing (detection of cancer 
and other disease biomarkers, polluting agents, bacteria, toxins) has increased making 
EIS one of the most preferred electrochemical techniques. 
6.2.3 Potentiometric biosensors 
Potentiometric sensors for the detection of infectious diseases have received a great 
deal of attention. This type of sensors have the longest history and are distinguished for 
having the largest range of applications33. Potentiometry with ion selective electrodes is 
a well stablished technique, frequently used in pharmaceutical, food, ambient, biological 
and other type of analysis90. 
Great efforts are being made to improve immunoassays to fit the requirements in clinical 
diagnosis. Potentiometric sensors are those that meet these characteristics the most. 
Besides being portable and affordable devices, they are highly selective and sensitive, 
easy to use and have been already applied in some clinical immunoassays91,92. Sensors 
with potentiometric transduction have unique characteristics and valuable possibility of 
measuring ionic activity, the measurement of a specie in a certain oxidation state with 
high analytical sensitivity, in a wide range of concentrations. Besides, the rapid response 
highlights this analytical technique for analytical control processes as a replacement for 
of conventional methodologies that are more expensive and time consuming.  
Potentiometric transduction is based on the measurement of potential differences 
occurring in the electrochemical cell composed by the reference and working electrode, 
both in contact with the sample, in electrical current absence. A change in electrode 
potential can be used as the quantifiable transducer response in potentiometric sensors. 
Potentiometric measurements provide a dependence between logarithmic concentration 
and potential. This detection method is sensitive, time-effective and economical.  
The activity alteration of an ion in solution results in an alteration in the chemical system 
potential that is measured relative to the reference electrode. The relation between ionic 
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specie activity and potential differences can be translated by the Nernst-Nicolsky 
equation (Equation 1):  
A
A
a
Fz
RT
EE log0      T=298,15K 
Equation 1: Nernst-Nicolsky equation. E  corresponds to potential difference obtained by the working electrode in 
relation to the reference electrode; E0 represents the sum of all contributions in the measurement cell, namely, selective 
electrode potential, potential of the reference electrode and liquid junction  independent of sample that corresponds to the 
abscises interception of the linear response; R is the rare gases constant, 8,3144JK-1mol-1; T is the absolute 
thermodynamic temperature , K; F is the Faraday’s constant, 9,64846x104Cmol-1; Az  is the primary ion charge; Aa  
represents the activity of the primary ion expressed in concentration units. 
6.2.4 Conductometric biosensors 
Conductometric biosensors rely on the fact that the majority of enzymatic reactions lead 
to the consumption or production of charged species, changing the ionic composition of 
the solution93.  
The conductivity of liquids results from the dissociation of the electrolyte into ions and 
the migration of the latter induced by an electrical field. When a potential difference is 
applied to the electrode, the electrical field regenerated induces the cations moves 
towards the cathode and the anions moves towards the anode. Thus, the current in the 
electrolyte is caused by the ion movement towards the electrodes and is determined by 
the sum of the ions present in the solution93.  
This type of biosensors does not require reference electrode, involve low voltage, involve 
inexpensive technology and permit the analysis of a wide spectrum of compounds93.   
7. Nanotechnology 
During the last decade, many research in the field of nanotechnology has been made, 
especially in the nanoparticles and optical detection methods. This top edge research of 
study can be applied to drug delivery, in vivo imaging (mainly in cancer diagnosis) and 
in vitro diagnosis (molecular diagnostic, single-cell or molecule identification/signaling, 
biomarkers detection)94,95. Nanotechnology involves the use of materials and systems 
on the nanometer scale, and nanodiagnostics are defined as the use of nanotechnology 
for clinical diagnostic purposes. The use of nanotechnologies for diagnostic applications 
intends to meet the sensitivity and cost-effectiveness required by clinical laboratory96.  
Most nanotechnology-based assays are adaptable to automation which makes them 
very appealing diagnostic tools. The fact that most biological molecules and cell 
organelles and structures fall within the nanometer scale empowers the potential of 
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nanodiagnosis, since it offers a wide range of tools and applications95,96. Nanoscale 
materials offer excellent prospects for designing powerful bioanalytical protocols with 
remarkable sensitivity and multiplexing/coding capability36,94. Nanoparticles possess 
certain size-dependent properties, particularly regarding optical and magnetic 
parameters which can be manipulated to achieve detectable signals. The signal 
enhancement associated with the use of nanoparticle amplifying labels and with the 
formation of nanoparticle-biomolecule assemblies provides the basis for ultrasensitive 
electrochemical detection36.  
Nanoparticle-based assays are based on the binding of a nanoparticle label to the target 
biomolecule that will produce a measurable signal or using nanoparticles as transduction 
materials. Nanotechnology promises to play an important role in the future development 
of diagnostic and therapeutic methods. However, many aspects of these 
nanodiagnostics techniques need to be evaluated further, especially the safety issues96. 
 
During this work, we tried to miniaturize the biosensor using screen-printed electrodes 
and make them biocompatible for in vivo measurements. Among other approaches, we 
started developing a biosensor that resorted to microfluidic devices as they possess 
great advantages as smaller quantities of test samples and reagents, drastic reductions 
in test times due to the possibility of automation of various process steps. 
 Our first approach for the immunosensor development was based on the immobilization 
of the protein of interest on magnetic microbeads modified with nitrilotriacetic acid 
(NTA).This technique resembles a flow cytometry protocol already established by our 
group52.  
In parallel, we focused on an exploratory study to evaluate the protein type and content 
present in exosomes, released in the different stages of disease (healthy humans, 
symptomatic patients, asymptomatic patients). These proteins could act as innovative 
biomarkers and be applied to biosensors, improving the sensitivity of these tools. 
The main goal of this work is to develop an accurate, specific and sensitive diagnosis 
tool capable of detecting early stages of disease and asymptomatic cases of canine 
Leishmaniasis. 
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Methods 
1. Reagents & Materials 
De-ionized or ultrapure water (conductivity < 0,1 µS.cm-1) was employed throughout this 
work and all chemicals were of analytical grade. Potassium hexacyanoferrate III, 
potassium hexacyanoferrate II trihydrate and sodium hydrogen phosphate dihydrate 
were obtained from Riedel-de Haën; acetonitrile and pyrrole were purchased from 
Sigma-Aldrich; lithium perchlorate anhydrous was obtained from Fluka Chemika; 
magnetic microbeads (5x107 mg/mL particles in the suspension) were purchased from 
Kisker Biotech GmbH & Co. KG; screen-printed carbon electrode DS110 (SPCE) were 
from Dropsens and NdFeB magnet with 15,7 N force were obtained from Supermagnete, 
Germany. Fetal Bovine Serum (FBS) was obtained from Lonza; Bovine Serum Albumin 
(BSA) was purchased from Sigma-Aldrich; reagent A (copper tartrate) and reagent B 
(Folin reagent) were purchased from Bio-Rad; RPMI base was obtained from Gibco; 
SDM-79 base97; hemin was obtained from Sigma-Aldrich and the centriprep Ultracel YM-
3 filtering units were purchased from Millipore. Nitrocellulose membranes were 
purchased from Bio-rad and ECL Plus chemiluminescent substrate was obtained from 
Amersham Bio-sciences.  Polyacrylamide, secondary antibodies (anti-dog and anti-
human IgG conjugated to horseradish peroxidase), Tween 20 and ο-phenylenediamine 
(OPD) were obtained from Sigma-Aldrich; hydrogen peroxide (H2O2) was purchased 
from Merck; HCl was obtained from Fisher Scientific. Preparation of Citrate Buffer was 
performed with citric acid monohydrate and trisodium citrate dehydrate both obtained 
from Sigma-Aldrich. Carbonate buffer solution was performed with sodium bicarbonate 
and sodium carbonate decahydrate from Sigma-Aldrich. Beads Latex aldehyde-sulfate 
4% w/v 4 µm Ref A37304 were purchased from Invitrogen. 
2. Immunosensor development 
2.1 Electrogeneration of a Poly(pyrrole)-NTA Chelator Film 
NTA-pyrrole monomer was synthetized according to the supporting information of the 
article “Electrogeneration of a Poly(pyrrole)-NTA Chelator Film for a Reversible Oriented 
Immobilization of Histidine-Tagged Proteins”98. 
The NTA- pyrrole monomer solution was prepared with 4 mM of this monomer in a 0,5 
M of lithium perchlorate anhydrous (LiClO4) and acetonitrile. 
A pyrrole solution (0,1 M) was prepared and dissolved in 0,5 M of lithium perchlorate 
anhydrous and acetonitrile. 
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Polymerization of both  NTA- pyrrole monomer and pyrrole solutions were tested with 
chronoamperometry, in which a 0,9 V current was applied for 5 seconds or 20 seconds 
until a polypyrrole film with the thickness of 1 mm was formed; and cyclic voltammetry, 
in which a repeated cycling over of potentials (3 scan rates) in a range of -0,5 V to 1,5 V 
at a scan rate of 0,1 V/s was performed with the same purpose. For this, a screen-printed 
carbon electrode (SPCE) was used and 100 μL of the described pyrrole solutions were 
deposited on the electrode. 
2.2 Development of an Electrochemical Immunosensor based on magnetic 
microbeads 
The magnetic microbeads are 1,7 μm size, spherical and paramagnetic in nature. These 
microbeads are easily retained when a magnetic field is applied and quickly resuspended 
when released from the magnetic force. It is also important to mention that no significant 
magnetism is retained after exposure to the magnetic fields. 
2.3 Preparation of antigen-coated magnetic microbeads  
47,2 µL of ultrapure water and 2,8 µL of beads were pipetted to an eppendorf and 
vortexed for 30 seconds. The beads were retained in the eppendorf with the help of a 
magnet (at least 30 seconds of contact) and the supernatant was aspirated with a 
micropipette; the beads were resuspended in 100 µL of ultrapure water and vortexed for 
10 seconds and the supernatant was removed as previously described. Then, the beads 
were resuspended again in 100 µL of PBS and the same procedure was followed. Finally, 
the beads were resuspended in 100 µL of PBS and posteriorly diluted 10 times to obtain 
5x106 particles/100 µL.  
50 µL of the previously described beads suspension were pipetted to an eppendorf and 
2,5 µg of CPX2 was added. Vortex gently for 20 seconds. The antigen incubation with 
the beads happened overnight (ON) at 4 ºC. Furthermore, the beads in each eppendorf 
were retained with the help of a magnet and the supernatant was removed. For blocking, 
100 µL of FBS 10% (in PBS) were added to the eppendorf and incubated 1h at 37 ºC. 
After the incubation, the washing steps previously described were performed twice with 
500 µL of PBS. 
2.4 Sample incubation 
100 µL of serum (diluted from a range of 1:15000 to 1:250 in PBS for canine sample, 
depending on the experiments) were added to each eppendorf containing the antigen-
coated magnetic microbeads and the samples were left to incubate for 30 minutes at 
room temperature (RT). 
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The samples were kindly provided by Dr. Luís Cardoso (UTAD). The symptomatic canine 
serums were obtained from dogs naturally infected with L. infantum from Portuguese 
endemic areas. 
2.5 Microfluidic platform incorporating magnetic field controller 
A magnetic field controller was designed and produced in our laboratory, as it is shown 
in Figure 7: 
 
Figure 7 - Magnetic field controller 
In parallel, a microfluidic platform was also designed and constructed.  
One channel (Øint=0,5 mm) was drilled in a single acrylic plate (3 x 2,5 x 0,5 cm) in order 
to be used to introduce the samples in the microfluidic platform and confined to the SPE. 
Perpendicularly, another channel was drilled with the same diameter as waste. The SPE 
surface that contains the reference, the working and the counter electrode was 
accommodated in a chamber, with 0,07 mm of height and with a Øint of 8 mm. This 
chamber was sealed with an O-ring with the same internal diameter. Another single 
acrylic plate with the same size and with the same dimensions of the chamber was 
coupled to the previous and the SPE was introduced in between. 
Flow lines were made with PTFE tubing (Øint=0,5 mm). The solutions were introduced in 
the microfluidic device by peristaltic pump (P), using a PVC tube with Øint=1,3 mm. The 
flow injection valve with a loop of 90 µL was controlled manually.  Flow injection analysis 
(FIA) system was chosen due to the simplicity of managing and as it provides 
reproducible volumes of samples, assuring the presence of the redox probe (Fe2+/Fe3+) 
to build the base line. Other aspect taken into account was the adjustment of the loop 
length (sample volume).  
The antigen-coated magnetic microbeads incubated with serum were introduced in the 
system through the loop of the FIA valve, propelled by a peristaltic pump. The 
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microbeads were injected through the flow lines till the arrival to the working electrode 
surface, where a magnetic field was activated. Below it is represented the assembly 
(Figure 8). 
 
Figure 8 - 1. Dropsens switch box and electrical connections; 2. FIA valve; 3. Microfluidic Platform; 4. Screen-printed 
carbon electrode with silver pseudoreference electrode; 5. Peristaltic pump; 6. Assembled system 
2.6 Measurements 
The electrochemical measurements were performed using a potentiostat (Metrohm), 
model Autolab PGSTAT10 and was controlled by GPES 4.9.005 software. For these 
measurements, screen-printed carbon electrodes were used. Working and counter 
electrodes were made of carbon and the pseudoreference electrode and electrical 
contacts were made of silver. The diameter of the working electrode was 4 mm. For 
electrochemical assays, the SPEs inserted in the microfluidic platform, were placed in a 
switch box (DROPSENS) and the electrical connections were introduced in the 
potentiostat. 
Square wave voltammetry (SWV), cyclic voltammetry (CV) and electrochemical 
impedance spectroscopy (EIS) measurements were conducted in a mixture of 1,0 
mmol.L−1 of [Fe(CN)6]3−/4− prepared in PBS buffer, pH 7,0. In these, the potential was 
scanned from −0,5 to +0,7 V, at 50 mV.s−1. In SWV studies potentials were changed 
from −0,5 to +0,7 V, at a 0,100 V.s−1, corresponding to a frequency of 25 Hz. 
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Impedimetric analysis was conducted in an Autolab PGSTAT204 in NOVA 1.10 software, 
using the same probe solution, at 110 mV, with a number of frequencies equal to 50 and 
of amplitude 0,01 V. The frequency range was 0,1–100 KHz. Data were fitted to a 
Randles equivalent circuit using the implemented ANOVA software. 
Below it is represented a scheme of the overall procedure (Figure 9): 
 
2.7 Protein quantification 
Protein quantification was based in a colorimetric assay similar to the well-Lowry 
assay. Several dilutions of a BSA containing from 0,125 mg/mL to about 4 mg/mL 
were performed to achieve a standard curve. The standard was prepared in the same 
buffer as the sample analyzed. 5 µL of standards and samples were pippeted to a 
microtiter plate and 25 µL of reagent A (copper tartrate) solution was added to each 
well. Then, 200 µL of reagent B (Folin reagent) was added into each well. Gently mix 
the samples and after 15 minutes, read absorbances at 750 nm.  
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Figure 9 - Experimental procedure scheme. Incubation of supermagnetic silica microspheres coated with 
nitrilotriacetic acid and nickel ions with the histidine tail of CPX2. Posterior incubation of antigen-coated microbeads 
with canine serums for 30 minutes; injection in the microfluidic platform with the magnetic field on and reading of 
samples in the SPCE resorting to cyclic voltammetry. 
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3. Identification of new promising markers from human plasma 
exosomes to detect leishmaniasis asymptomatic cases 
3.1 Recovery of extracellular material from L. infantum 
Promastigotes used for exoproteome studies were maintained in cRPMI (RPMI base 
complemented with 10% SDM-79 base and 2,5 μg/mL of hemin), a medium developed 
by our group and validated for exoproteome studies. All cultures were grown with a 
starting inoculum of 1 × 106 parasites. 
Logarithmic promastigotes with a startup inoculum of 1 × 106 in cRPMI were grown and 
the culture medium was recovered at 96 h. The parasites were removed by centrifugation 
followed by filtration through a 0,4 μm filter. The exoproteome was centrifuged at 10.000 
g for 10 min at 4 °C to remove cellular debris, and further centrifuged at 100.000 g for 3 
h. The vesicle depleted exoproteome (VDE) was recovered without disturbing the vesicle 
pellet, and then the final 1 mL of residual volume was decanted and discarded leaving 
only the vesicle pellet that was resuspended in 500 μL of PBS. The vesicles (EVs) were 
stored at either 4 °C or −90 °C depending on further intended use. The recovered VDE 
was concentrated to a residual volume of 500 μL using centriprep Ultracel YM-3 filtering 
units (Millipore). The samples were dialyzed twice against PBS using the same YM-3 
filtering devices. After the second dialysis step, the VDE was again concentrated to a 
residual volume of 500 μL and stored at −90 °C (Figure 10).  
 
Figure 10 - Experimental procedure to recover extracellular material of Leishmania infantum. 
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3.2 Western blot analysis 
Leishmania EVs and VDE were run on 10% polyacrylamide gels and transferred onto 
nitrocellulose membranes. The blots were blocked overnight in 5% skimmed milk in PBS. 
Dog serums and human serums were diluted 1:250 in PBS containing 0,1% Tween 20 
(PBS/Tween) and incubated for 1 h with the membranes. The blots were washed three 
times for 5 min in PBS/Tween and incubated with horseradish peroxidase-conjugated 
anti-dog/anti-human (1:500). The blots were washed as above, incubated with ECL Plus 
chemiluminescent substrate and exposed using the Chemidoc XRS system (Biorad). 
3.3 ELISA - Enzyme-Linked Immunosorbent Assay  
Flat-bottomed microtiter plate was coated with extracellular material (total exoproteome; 
extracellular vesicles; and vesicle depleted exoproteome) in a range of 0,0002 μL to 20 
μL or soluble promastigote Leishmania antigens (SPLA) all diluted in 0,05 M carbonate 
buffer (pH=9,6) and dispensed 50 µL/well. The plates were incubated overnight at 4ºC. 
Posteriorly, the plates were washed several times with PBS-Tween (0,05%) and blocked 
with PBS-low-fat-milk (3%), for 1h at 37ºC. The plates were washed with PBS-Tween 
(0,05%) and positive and negative canine serums were diluted (1:1500) in PBS-Tween 
(0,05%)-low-fat-milk (1%) and incubated for 30 min at 37ºC. After washing the plates, 
the incubation was proceeded with secondary antibody (anti-dog/ anti-human IgG 
conjugated to horseradish peroxidase) diluted in PBS-Tween (0,05%)-low-fat-milk (1%) 
for 30 minutes at 37ºC, in dark. The plates were washed and the product was developed 
for 10 minutes in the dark at room temperature (RT) using ο-phenylenediamine (OPD) in 
citrate buffer as substrate and hydrogen peroxide (H2O2) as reactive oxygen metabolic 
byproduct. Reaction was stopped with of HCl 3M and absorbance values were read at 
492 nm in an automatic reader. 
3.4 Sample collection  
Plasma samples from symptomatic and asymptomatic Leishmania patients, were 
provided by Javier Morena from Institute de Salut Carlos III in Madrid, Spain (Table 1). 
As negative controls, it was used plasma from healthy donors, to compare the profiles of 
the infected and not infected patients.  
32 FCUP 
Development of an innovative immunosensor for Leishmaniasis screening 
Table 1 - Plasma samples from negative controls; asymptomatic; symptomatic and healed visceral leishmaniasis patients. 
 
All the samples were stored in aliquots at -80 °C until the isolation of extracellular vesicles 
(EVs). Before performing the isolation of EVs, using Size Exclusion Chromatography 
(SEC), plasma samples were centrifuged twice at 2000 g for 10 min at 4 °C to avoid the 
presence of fibrins in the columns.  
3.5 Plasma-EVs Isolation by SEC 
A small aliquot of each sample before loading was kept to measure the total particle 
concentration by NTA.  
Extracellular vesicles were isolated from 100 μL or 1 mL of platelet-free plasma samples 
using SEC.  This method involved the preparation of a “homemade” Sepharose CL-2B 
column (1 mL or 10 mL) and the collection of serial fractions of the plasma samples.  The 
SEC procedure was performed as previously described99. SEC would permit the 
separation of the extracellular vesicles by size and the first fractions would be enriched 
in the higher sized vesicles (microvesicles), then the exosomes enriched fractions would 
be obtained and further soluble protein fractions would be eluted. 
Protein concentrations of the chromatographic fractions were measured by 
spectrophotometer NanoDrop (Thermo ScientificTM). 
3.6 Exosome-characterization: Bead-based assay for FACS analysis 
This method was performed based on conjugation of latex microbeads with extracellular 
vesicles of different sample origin and antibody coupling for FACS analysis. The 
exosomes obtained from plasma or culture, and isolated by SEC, were coupled to latex 
microbeads and then incubated with antibodies to detect the presence of exosome 
markers in our preparations.   
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The exosomes were labeled with fluorophore-conjugated antibodies and analyzed by 
FACS. For these characterizations, it was used CD5L and CD71 antibodies for the 
detection of exosome markers in our plasma samples, as they were previously used by 
the group for this type of identification. CD63 antibody was tried out to detect the 
presence of extracellular vesicles in the supernatant of promastigotes culture.  
Samples were analyzed using a FACSverse flow cytometer (BD Biosciences, San Jose, 
CA, USA) and flow cytometry data were analyzed with the FlowJo software.  
3.7 Nanosight 
This technique measures the rate of Brownian motion of the nanoparticles using a NTA-
Nanosight LM10 system (Malvern Instruments Ltd, Malvern, UK). The instrument is 
equipped with a 638 nm laser, a system of video capture and a particle-tracking software. 
It is used to determine EVs concentration and size. The fractions with highest 
fluorescence values to CD71 (exosome enriched fractions) were analyzed in this 
equipment. To obtain an accurate determination of the concentration and size of the 
vesicles the number of particles per frame must be in a range from 20 to 150. This implies 
making dilutions of the chosen samples to get the results. 
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Results 
As mentioned before, one of the most crucial and important steps of building an 
immunosensor is to do the correct immobilization of the protein of interest. It was decided 
the use of CPX2 as the protein to be immobilized as it had already been synthetized in 
our laboratory and we had considerable volume to do several assays and run preliminary 
experiments. Although not being the more sensitive recombinant protein regarding 
symptomatic canine serums, CPX2 showed good results when it came to detect 
asymptomatic canine serums in ELISA. Furthermore, CPX2 alone could not be the best 
protein to immobilize in the immunosensor or could require the presence of other antigen 
but taking into account the resources available it was the best candidate to run the trials. 
Regarding this matter, in this work three different approaches were followed:  
1. Electrogeneration of a Poly(pyrrole)-NTA for Histidine-Tagged 
Proteins Immobilization  
Conducting polymers are suited to the development of electrochemical biosensors as 
they provide immobilization of biomolecules maintaining its activity and also allow rapid 
electron transfer100. Among them, polypyrrole has good conductivity and good stability, 
which makes it a good polymer to produce conductive films101,102,103.  
Immobilized metal-ion affinity chromatography (IMAC) uses transition metal complexes 
of NTA to purify proteins with histidine tails. In resemblance to this technique, our aim 
was to immobilize an antigen through the formation of a complex between the ligands of 
the NTA and the protein histidine-tag104. 
NTA is a chelator that coordinates bivalent metal cations such as Cu2+and Ni2+ leaving 
free coordination sites of the chelator-metal complex for the binding of histidine-tagged 
proteins104. Since NTA immobilization needs to be orientated to complexation occur, the 
synthesis of this derivate of polypyrrole should allow the special control of NTA without 
compromising conductivity and also the reversible ligation of histidine-tagged proteins. 
 
Figure 11- Schematic Representation of the Reversible Immobilization of Histidine-Tagged Biomolecules to an 
Electrogenerated Poly(pyrrole)-NTA Film98. 
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After the synthesis and the characterization of the pyrrole NTA monomer by nuclear 
magnetic resonance, it was our aim to analyze the electrochemical behavior of the 
synthetized monomer. 
According to “Electrogeneration of a Poly(pyrrole)-NTA Chelator Film for a Reversible 
Oriented Immobilization of Histidine-Tagged Proteins” a novel approach that enabled the 
protein immobilization via coordination of Cu2+ and histidine-tagged proteins through the 
synthesis and electropolymerization of a pyrrole N-substituted by a nitrilotriacetic acid 
was described.  The electropolymerization of the monomer was described by doing 
repeated potential cycling over the range of 0-0,8 V and with the appearance of an 
oxidation peak at 0,18 V that clearly indicated the formation of a polymeric coating98. 
However, when performed in our lab, neither the formation of the peak or the polymer 
film by cyclic voltammetry was observed. Thereafter, it was decided to increase the 
amount of probe used to certify that there was enough amount of electron transfer to 
allow redox reactions and the formation of the polymer. An increased concentration of 
the monomer was also tested and none of the approaches lead to the formation of the 
polymer. 
Several questions were considered concerning different aspects of preparation and 
polymerization of the synthetized polymer, such as purity/quality of the reagents and the 
organic synthesis that was followed by the detailed experimental part of the scientific 
article98. To guarantee that there weren’t any problems concerning the electrode surface 
or electroanalytical procedure and/or equipment, an electrochemical coating of the 
conductive support on a SPE was performed with pyrrole by doing a chronoamperometry 
with the formation of a polypyrrole film with 1 mm of thickness. Moreover, we performed 
potential cycling over the range of -0,5-1,5 V and we still visualized the polymer film 
formation. 
To overcome these problems new monomer solutions and different conditions in the 
chronoamperometry parameters were tested without any success. According the 
author98 there were some mistakes in the experimental report and the synthesis of 
pyrrole NTA monomer was impossible to perform. No more work was invested on this 
immobilization strategy. 
2. Immobilization of antigen in magnetic microbeads 
As an alternative, it was followed the immobilization strategy used in cytometry by our 
group52, using magnetic microbeads that allow the antigen binding (currently the 
recombinant protein CPX2). 
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Magnetic microbeads are becoming a great approach in biosensors, namely in 
immunosensors. They produce stable and inexpensive devices, rapid and easy to 
operate105. Electromagnets can pull immuno- substituted beads towards a binding site 
and the species that do not bind can be removed by rinse. The major challenge with 
magnet microbeads associated with immunosensors is the construction of the device. 
Once assembled, the operation of the system is simple106. 
This particular type of magnetic beads have a Fe3O4 core, which confers them the 
magnetic properties, covered by silica. This silica surface (with hydroxyl groups) is then 
derivatized with the chelating ligand nitrilotriacetic acid (NTA). In turn, NTA will allow the 
immobilization of divalent nickel ions (Ni2+), essential for the formation of covalent bonds 
with the histidine tail of the protein (Figure 12). 
The immobilized metal affinity beads offer high binding capacity and, as mentioned 
before, they can be used for small scale affinity purification as well as high-throughput 
screening of recombinant his-tagged proteins.  
The polyhistidine tag is the most popular affinity tag and consists of six consecutive 
histidine residues64. The assays were initiated with CPX2 since previous results had 
shown good specificity and sensitivity for symptomatic and asymptomatic patients23. 
Our approach was to test the flow cytometry protocol adapted to an immunosensor with 
electrochemical transducer. Thus, it was investigated the electrochemical response of 
the prepared immunosensor against negative serum (non-infected dog for 
leishmaniasis), positive serum (symptomatic dog with leishmaniasis) and superpositive 
serum (symptomatic dog with high titer). For that purpose, electrochemical impedance 
spectroscopy was used and the results are presented in Figure 13: 
Supermagnetic silica 
microspheres 
Fe
3
O
4
 -OH 
Figure 12 - Representation of the supermagnetic silica microspheres with Fe3O4 core covered by hydroxyl groups coated 
with nitrilotriacetic acid and nickel ions and respective chelation with histidine residues of proteins of interest. 
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Figure 13 - Graphical representation of a negative, positive and superpositive serums measured by Electrochemical 
Impedance Spectroscopy (EIS). Zimag represents the imaginary part of impedance and Zreal represents the real part of 
impedance. 
According to the graphical representation, only the diffusional controlled region of the 
Nyquist plot was observed. There was no formation of a semi-circle, which might indicate 
that the sensing layer formed in the working electrode surface (magnetic microbeads 
layer) was not efficient to cause charge transfer resistance (Rct). Therefore, the steric 
barrier presented to the redox probe at the surface of the electrode was not enough to 
trigger a response79. On the other hand, this electrochemical technique must be more 
explored with biosensors incorporating magnetic microbeads, since there are few articles 
describing these procedures and the majority of them is applied to enzymatic 
biosensors107,108.  
For those reasons, it was decided the reproduction the same protocol but this time with 
cyclic voltammetry as measurement technique, to investigate if this method was sensitive 
enough to differentiate the samples (Figure 14). 
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Figure 14 - Graphical representation of a negative, positive and superpositive serums measured by cyclic voltammetry. I 
(A) represents current measured in amperes and E (V) represents potential measured in volts. 
It was clear the visualization of differences between negative, positive and superpositive 
samples. The absence of antibodies in the serum to bind to the CPX, immobilized in the 
magnetic microbeads in the sensor surface, results in a thinner layer that enables a 
higher oxidation/reduction peak intensity due to less charge transfer resistance. It is also 
noticeable that higher titer samples result in more anti-Leishmania antibodies binding to 
CPX2. The layer presented to the redox probe is thicker which presents itself as minor 
current (less electron transfer and electrons achieving the electrode surface). 
For comparison purpose, square wave voltammetry was considered. In Figure 15 it is 
presented a compilation of voltammograms that were obtained by using different positive 
serum dilutions, a negative serum and as “blank” PBS (used to dilute samples).  
 
Figure 15 - Graphical representation of several dilutions of a positive serum obtained by Square Wave Voltammetry 
(SWV). I represents current measured in amperes (A) and E represents potential measured in volts (V). 
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Once again, it is possible to distinguish the positive and negative serums as well as 
differentiate different antibody titers of a positive serum. After the serum incubation there 
was a change in the potential of the electrode probably because of the established 
kinetics barrier between [Fe(CN)6]4−/3− and the charge of the antigen/antibody complex. 
Even more, the intensity of the current is proportional to the antibody concentration. The 
electron transfer resistance at this structure was expected to be higher relative to high 
antibody concentration. However, a higher oxidation peak current was observed at high 
antibody concentrations. More studies must be done to understand these results. 
To improve the assembly of a stable and accurate immunosensor based on magnetic 
particles, a flow device to be coupled in a flow injection analysis was evaluated to 
guarantee reproducible volumes of magnetic microbeads suspension.  
Development of a magnetic field controller coupled to a microfluidic platform  
First, it was designed and built an electrical circuit (magnetic field controller) that allows 
the creation of a magnetic field (on/off configuration) (Figure 7). In parallel, a microfluidic 
platform was designed and manufactured to allow the samples feeding to the electrode 
(propelled by a peristatic pump). Coupling the magnetic field controller to the base of the 
working electrode (confined in the microfluidic device) will permit the retention of the 
magnetic microbeads with further serum incubation. This strategy will leverage a more 
sustainable procedure because of the reutilization of the electrode (screen-printed 
electrode) through several samples, decreasing also the cost of the analysis, more 
precision and in “green chemistry” concept. 
The coupling of the microfluidic platform to the flow injection analysis system (FIA) 
enables reproducible volumes of sample and therefore minimize the waste of reagents.  
In this phase of the development of a biosensor, optimization of many parameters is 
essential to the good function of the same. Antigen-beads proportion and incubation 
were already optimized, as well as blocking, by our group in “Development of a 
Fluorescent Based Immunosensor for the Serodiagnosis of Canine Leishmaniasis 
Combining Immunomagnetic Separation and Flow Cytometry”52. Other parameters such 
as the hydrodynamic conditions through the SPCE (flow rate, volume of the loop, time); 
the voltammetry scan rate and the ON/OFF time period of the magnetic field applied to 
the magnetic microbeads still had to be studied and stablished. 
Following the assembly of the system, the first trial was performed with the serum of a 
non-infected dog and with several dilutions of an infected dog serum. The immobilization 
of CPX2 and wash steps were performed outside the system. Then, the magnetic 
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microbeads immobilized with CPX2 antigen were introduced in non-studied size loop of 
the FIA valve (30 μL) and were injected into the microfluidic device while the magnet was 
active. The incubation of the serum on the magnetic microbeads previously prepared 
was done in the flow system by injecting the samples (serums containing or not 
antibodies anti-Leishmania). The system was stopped for 30 minutes while the magnet 
was active. As the serum samples were diluted in the redox probe used in that assay 
(Fe2+/Fe3+) it was possible to obtain a voltammogram after the period of incubation. The 
results can be seen in the figure bellow (Figure 16). 
 
Figure 16 - Graphical representation of several dilutions of a positive serum obtained by cyclic voltammetry (CV). I 
represents current measured in amperes (A) and E represents potential measured in volts (V). 
As we can observe, there was a tremendous increase of the capacitive currents. This 
type of current doesn’t obey to Faraday’s law and is not proportional to the concentration 
of analyte. The contact of the serum with the carbon surface promotes the unspecific 
adsorption of the antibodies, leading to the formation of a biochemical layer that 
increases the electron transference resistance.  
As this increase in the capacitive currents was probably due to the binding of antibodies 
to the electrode surface, a different approach was thought and executed. Thereby, the 
preparation of the magnetic microbeads and the coupling of the antibodies to CPX2 were 
performed outside the system. Once the incubation of the beads was done outside, they 
were resuspended in PBS to guaranty the conformational stability of the proteins and the 
redox probe was used as carrier. Thus, the samples were in contact with the SPCE 
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during the measurement time and were rinsed after obtaining the voltammogram, by the 
deactivation of the magnetic field. 
Moreover, an experiment with the serums incubation outside the system was performed 
to try to avoid high capacitive currents. Several dilutions of a symptomatic canine 
Leishmaniasis serum were characterized by cyclic voltammetry, as seen in Figure 17: 
 
Figure 17 - Voltammograms obtained with several dilutions of a positive serum resorting to cyclic voltammetry. I represents 
current measured in amperes (A) and E represents potential in volts (V). 
According to the voltammograms (Figure 17) it was possible to identify a shift of the 
potential. More concentrated samples lead to bigger shifts and higher values of potential 
looking to be related with Nernstian response. Thus, these results were analyzed 
according equation 1, in which the potential follows a linear regression with the logarithm 
of the activity (antibodies concentration) (Figure 18). 
 
Figure 18 -Calibration curve obtained with Nernst equation, in which potential (E) in volts (V) is dependent of the logarithm 
of concentration (Log (C)). The linear regression was obtained with several dilutions of the same positive sample. 
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There is in fact a correlation of potential against the concentration of the several dilutions 
of the positive serum. This correlation is linear up to the 1:10000 dilution. The titer of 
each sample will depend on the quantity of antibodies anti-Leishmania and the fact that 
response is obtained with such diluted samples indicates that this method may be quite 
sensitive. 
This experiment was followed by the optimization of some parameters since it was crucial 
to establish the conditions that lead to the best response possible. 
The first optimized parameter was the volume of sample. Different volumes of sample 
were tested in a range from 45 μL to 540 μL, to evaluate which was the most appropriate 
to use with this type of system and electrode and which one gave the best correlation. 
The optimal volume of sample was 90 μL, since it was the one in which the shift in the 
potential was more accentuated. Higher volumes didn’t introduce any improvements in 
the potentiometric response. 
Once again, the voltammograms present a shift in the potential against the concentration 
of the several dilutions of the positive serum, correlating with the Nernst equation (Figure 
20).  
90 μL 
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Figure 19 - Voltammograms of a negative serum and several dilutions of a positive serum obtained with 90 μL 
of sample resorting to cyclic voltammetry. 
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Figure 20 - curve obtained with Nernst equation, in which potential (E) in volts (V) is dependent of the logarithm of 
concentration (Log (C)). The linear regression was obtained with several dilutions of the same positive sample. 
Moreover, we could clearly distinguish the negative serum from the positive serum 
dilutions as the potential of the negative serum was lower than the more diluted sample 
of the infected canine serum, due to the lack of antibodies anti-Leishmania in the 
negative serum sample. 
The slope was very close to the theoretical value (59,2 mV) which is in accordance with 
the type of redox probe used (Fe2+/Fe3+). Nevertheless, it was verified that the slope was 
quite different from the previous one. Further studies were performed to investigate this 
irreproducibility of the slope. 
Other parameter to be optimized was the scan rate, since it influences electrochemical 
response. This concept is defined as the time that takes to sweep the potential range. 
This parameter can influence the interpretation of results since, for example, high scan 
rates peaks have large current and high resistance that might result in distortions and 
misinterpretations of results.   
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So, different scan rates (50 mV; 100 mV; 200 mV) were evaluated to perceive which one 
gave the best correlations.  
After proceeding to the same protocol several times it was concluded that the scan rate 
of 50 mV/s was the more adequate to our experiments (Figure 21) since the coefficient 
of determination (r2) was closer to 1, the slope was near the theoretical nernstian slope 
(59mv.dec-1) and a higher concentration range was identified. 
Meanwhile, background noise appeared during calibration measurements due to the 
damage of the electrical circuit (magnetic field controller). A new magnetic field controller 
and a new microfluidic platform were constructed in a more robust approach. 
Several calibrations with positive and negative serums were performed but were always 
irreproducible. Most of the time no linear relation was found between potential shift and 
titer of antibodies. It was discussed possible causes that were affecting the results.  
We wondered if the change of the miniaturized device could influence them, but after 
using the system carefully and with the appropriate management the results were still 
irreproducible. 
Figure 21 - Three calibration curves obtained with several dilutions of a positive canine serum at a scan rate 
of 50 mV. They were obtained with Nernst equation, in which potential (E) in volts (V) is dependent of the 
logarithm of concentration (Log (C)). 
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Two main questions are related with the biochemical stability of the proteins used in this 
work (the effect of storage time and freeze-thaw cycles) and the type of serum containers 
used to aliquot the sample (the containers could adsorb protein to the surface). The 
quantification of the proteins was made according section 2.7 of Methods; and an 
experiment was performed with the serum from the original containers and from one of 
the aliquots. Potentiometric calibrations were performed and the results were almost 
overlapping. That excluded the hypothesis that the irreproducibility between calibrations 
was due to the protein content in the serum. 
To overcome random errors special attention was given to the dilutions of the samples 
and this change in the preparation of samples slightly improved the results, although with 
fluctuations in slope, as it is possible to observe in Figure 22. 
 
Figure 22 - Calibration curves obtained with several dilutions of a positive canine serum after optimizing some parameters. 
They were obtained with Nernst equation, in which potential (E) in volts (V) is dependent of the logarithm of concentration 
(Log (C)). 
One of the main reasons to build a microfluidic platform was to ensure reproducible 
volumes, as well as to reduce the cost of the analysis by using the same SPCE to analyze 
several samples. Thus, two consecutive calibrations were performed with the same 
electrode. It was noticed that the slope changed a lot from the first calibration to the 
second. Also, we noticed that the second calibration started with a similar potential to 
the last sample of the first calibration (Figure 23). 
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Figure 23 - Two consecutive calibration curves with the same sample dilutions of a positive canine serum. They were 
obtained with Nernst equation, in which potential (E) in volts (V) is dependent of the logarithm of concentration (Log (C)). 
The experiment was repeated and the same situation was observed; the second 
calibration began with the potential of the last sample of the first calibration. That meant 
that some phenomena was promoting a change in the electrode surface. Even though 
the system was washed between samples with the magnet off (to allow the rinse of all 
magnetic nanoparticles and other impurities that the sample might contain), something 
was shifting the potential. So, two experiments were performed to see what was causing 
the potential shifting. First, the non-coated magnetic microbeads were used and the 
measurements were done exactly in the same way as it was done with the previous 
samples (Figure 24). 
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Figure 24 - Voltammograms corresponding to the results of a cyclic voltammetry of the same sample – beads. I represents 
current measured in amperes (A) and E represents potential in volts (V). 
As observed, there was no alteration in the potential from one sample to the next one. 
The absence of potential shift indicates that the magnetic beads are not the responsible 
element for change of the electrode surface. 
After excluding the possibility of the magnetic microbeads as source of the electrode 
surface damage, a similar approach with CPX2 coated magnetic microbeads (overnight 
incubation) was performed. This would allow the evaluation of the antigen influence on 
the potential shifting and the reuse of the electrode (Figure 25). 
 
Figure 25 - Voltammograms corresponding to several readings of the same sample - microbeads immobilized with CPX2. 
I represents current measured in amperes (A) and E represents potential in volts (V). 
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It is evident that after passing the same sample through the electrodes multiple times, 
there is a potential shift. Even when the washing steps are properly executed, this still 
leads to a shift in potential. This completely explains the different responses from the first 
to the second calibration and the fact that samples with the same concentration don’t 
have the same potential. In this case CPX2 looks to be adsorbed to the electrode, 
changing the potential. This makes the measurement of samples and the calibration 
impossible. Therefore, approaches to enable the cleaning of the electrode surface were 
thought. Trypsin is known for its capability of splitting cells and detaching cells and other 
biomolecules from flasks and other plastic/glass surfaces. So, this reagent was 
evaluated for its ability of revert the adsorption occurring in the electrode surface. After 
testing this option, it was realized that trypsin does not reverse the electrode surface 
(potential shift cannot be reversed). It is our aim to evaluate the use of an acetate buffer 
at pH 4 to clean the carbon surface of the electrode; blocking of the carbon surface with 
BSA or even to do a direct covalent binding of the antigen to the carbon electrode 
surface. 
In parallel, experimental work in the identification of new biomarkers was performed, 
namely by recovering exosomes from human plasm samples. 
3. Identification of new promising markers from human plasma 
exosomes to detect Leishmaniasis asymptomatic cases 
The proteic material in extracellular vesicles has been used as novel biomarkers in the 
diagnosis of several diseases. Thus, in this work extracellular material from L. infantum 
was recovered to access the potential of the different exoproteome fractions of this 
parasite and evaluate its use as markers in this infectious disease.  
To respond to these questions, it was decided to perform an ELISA with the several 
fractions recovered from the L. infantum culture: total exoproteome (EXO); extracellular 
vesicles (EVs) and vesicle depleted exoproteome (VDE). These fractions were coated in 
the plates and soluble promastigotes Leishmania antigens (SPLA) were used as a 
control to the experiment. Different volumes of extracellular material (20 μL 
corresponding to 1x; 2 μL to 10 times dilution – 10x; and 0,2 μL corresponding to 100 
times dilution - 100x) were used and each of them incubated with a well characterized 
positive canine leishmaniasis serum (+) and a negative canine leishmaniasis serum (-). 
Canine serums were used to do the preliminary experiments because human samples 
are a lot more difficult to get and we have limited volumes of samples. 
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Figure 26 - Averages of the absorvance using ELISA technique of different exoproteome fractions (Total exoproteome - 
EXO; Extracellular vesicles - EVs; Vesicle depleted exoproteome - VDE) and Soluble Promastigote Leishmania antigens 
(SPLA) against positive canine serum (+) and negative canine serum (-) for Leishmaniasis. The second column of each 
fraction was diluted 10 x and the third column was diluted 100 x. 
In Figure 26, it is observed high reactivity of the secreted material against positive canine 
serum and nearly no response is seen when the fractions are incubated with a non-
infected dog serum (negative serum). Also, the same response is obtained with SPLA 
which corroborates our experiment. Furthermore, the positive canine serum has a higher 
reaction with the EVs fraction when compared to the VDE fraction. 
Regarding ratio between positive (+) and negative (-) canine serum samples, we can 
conclude that better correlation is achieved with more diluted samples (100 x) (except 
for the VDE fraction, but this might be due to the washing steps of ELISA that weren’t 
performed with the same efficacy when compared with the other fractions) (Figure 27). 
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Figure 27 - Ratio of the absorvance between the positive (+) and the negative (-) canine serum responses for different 
exoproteome fractions (Total exoproteome - EXO; Extracellular vesicles - EVs; Vesicle depleted exoproteome - VDE) and 
against Soluble Promastigote Leishmania antigens (SPLA). The second column of each fraction was diluted 10 x and the 
third column was diluted 100 x. 
In order to get more information, a western blot was performed with the EVs and the VDE 
fractions. Different volumes of these fractions were used to investigate which one was 
the best, as this type of assay had never been done by the group before with this type of 
samples. The experiments were done with two different membranes, one of them 
incubated with a positive dog for Leishmaniasis and the other membrane was incubated 
with a negative serum (healthy canine). 
As it is visualized in Figure 28, two bands appeared around 90 kD and 120 kD. There is 
some background, as it is possible to see in the membrane regarding the negative canine 
serum. One possible explanation is the quite a lot of extracellular material (50 μL of 
EVs/VDE) used in those wells. Furthermore, the blur circled in blue is characteristic of 
the presence of some abundant proteins released by Leishmania infantum involved in 
its virulence factors such as GP63 and also a protein known as beta-fructofuranosidase 
involved in carbohydrate metabolism. 
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Stripping of the membrane was performed and two different serums were incubated. The 
results are presented in Figure 29. The negative canine serum didn’t give any 
background and the positive serum presented two bands in the well with 5 μL of 
extracellular vesicles. However, these two bands are not overlapping with the bands from 
the previous western blot, which indicates that for different serums the profile of the 
bands is different.  
 
Figure 29 - Western blot after stripping the membrane and doing incubation with different serums for the wells 
corresponding to EVs and VDE fractions (5 μL and 0,5 μL of extracellular material). 
 
Positive Canine Serum Negative Canine Serum 
EVs VDE MM EVs VDE MM 
Positive Canine Serum Negative Canine Serum 
132 Wendel 539  
Figure 28 - Results of the Western Blot with different volumes (50 μL; 5 μL and 0,5 μL) of EVs and VDE fractions against 
different serums - positive canine serum (left image) and negative canine serum (right image) 
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In order to evaluate the optimal quantity of extracellular material to be plated in an ELISA, 
different volumes (0,0002 μL; 0,002 μL; 0,02 μL; 0,2 μL; 2 μL) were considered. The 
better OD ratios were obtained with 0,2 μL of extracellular material (Figure 30). Once 
more, EVs present a higher response against the canine positive serum when compared 
to VDE fraction.  
 
Figure 30 - Ratio between response against positive canine serum (+) and negative canine serum (-) with different 
fractions of exproteome of Leishmania infantum (Total exoproteome - EXO; EVs - extracellular vesicles; VDE - vesicle 
depleted exoproteome) for different volumes of extracellular material. 
Since the exploratory research with canine serums was encouraging it was our aim to 
proceed the study with human samples against extracellular material obtained from the 
culture of L. infantum, EXO, EVs and VDE, and against SPLA. As a preliminary 
experiment, an ELISA was performed with 2 μL of the same extracellular material against 
human samples. This volume increment was to guarantee the signal achievement 
(Figure 31). 
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Figure 31 - Results of an ELISA for exoproteome fractions (EVs - extracellular vesicles; VDE - vesicle depleted 
exoproteome) and SPLA - soluble promastigotes Leishmania antigens against human samples from an infected and a 
non-infected patient.  
Over again there was reactivity of SPLA and exoproteome fractions (EVs and VDE) 
against the infected Leishmaniasis patient whereas no response was obtained with non-
infected Leishmaniasis patient plasma. This indicates that there are proteins in the 
extracellular material of L. infantum reacting against Leishmaniasis infected patients 
sample, showing once more the potential of EVs as possible biomarkers for 
Leishmaniasis diagnosis. EXO is not presented in Figure 31 since the assay resulting 
color was too saturated and optical density could not be measured. 
Proteins associated with EVs (including Exosomes) secreted by infective L. infantum 
have been previously identified in cell culture supernatants by our group, but never in 
human samples. Thus, it is our goal to identify proteins in Exosomes isolated from 
healthy patients (negative controls) and plasma of Leishmaniasis symptomatic and 
asymptomatic patients.  
3.1.  Isolation and characterization of exosomes from negative controls 
Firstly, isolation and characterization of the exosomes enriched fractions from negative 
controls were performed. The exosomes (EXos) were isolated from 100 µL plasma 
samples. The isolated fractions were obtained with a 1 mL sepharose column through 
size exclusion chromatography (SEC) and analyzed by bead-exosome FACS assay 
using CD71 marker, a marker used for the detection of exosomes in plasma (Figure 32-
34): 
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Figure 33- Protein quantification (●) by nanodrop (Abs 280 nm); Bead-based assay for FACS analysis (●) for fractions 1-
10 obtained from SEC for sample 2CA (negative control) and respective controls. Fr5 and Fr6 represent fractions 5 and 
6  
 
Figure 33- Protein quantification (●) by nanodrop (Abs 280 nm); Bead-based assay for FACS analysis (●) for fractions 1-
10 obtained from SEC for sample 2CA (negative control) and respective controls. Fr5 and Fr6 represent fractions 5 and 
6 with a concentration of proteins of 0,049 and 0,153 μg/μL, respectively. C1 (-) -  exosomes + beads + isotype (1:5000) 
+ secondary antibody; C2 (-) -  beads + Isotype (1:5000) + secondary antibody 
 
Figure 34 - Protein quantification (●) by nanodrop (Abs 280 nm); Bead-based assay for FACS analysis (●) for fractions 1-
10 obtained from SEC for sample 3AF (negative control) and respective controls. Fr5 and Fr6 represent fractions 5 and 6 
with a concentration of proteins of 0,082 and 0,266 μg/μL, respectively. C1 (-) -  exosomes + beads + isotype (1:5000) + 
secondary antibody; C2 (-) -  beads + Isotype (1:5000) + secondary antibody 
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Figure 32 - Protein quantification (●) by nanodrop (Abs 280 nm); Bead-based assay for FACS analysis (●) for fractions 1-
10 obtained from SEC for sample 1AT (negative control) and respective controls. Fr5 and Fr6 represent fractions 5 and 6 
with a concentration of proteins of 0,109 and 0,375 μg/μL, respectively. C1 (-) -  exosomes + beads + isotype (1:5000) + 
secondary antibody; C2 (-) -  beads + Isotype (1:5000) + secondary antibody 
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From the results of nanodrop, similar profiles in all negative controls were visualized. The 
protein concentration starts to rise in fractions 5/6 which indicates that fraction 5 is 
probably enriched in EXos, since previous results showed that the fractions with more 
EXos are the ones before the accentuated rise in protein concentration. 
As expected, the fractions with more isolated EXos were fractions 5 and 6, as it was 
confirmed from the beads based assay performed with CD71 marker. 
The same assay with CD5L marker was also performed but the control with the isotype 
had high background making impossible to interpret the results (data not shown). 
From the negative controls, the fractions that had the highest response to CD71 were 
analyzed by nanosight (Figure 35).  
 
 
 
 
 
 
 
 
 
 
 
FR6 - 7.66 × 10
10
 particles/mL 
1AT 2CA 
FR6 - 3.33 × 10
10
 particles/mL 
3A
F 
FR5 - 7.7 particles/frame 
Figure 35 - Nanosight profile for the negative controls (1AT, 2CA, 3AF). Size and concentration information for the fraction 
with more EVs. 
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The size and concentration of the analyzed samples for the fractions that were most 
enriched in exosomes can be observed in Table 2: 
Table 2 - Size (mode) and concentration (particles/mL or particles/frame) of the fractions (FR) enriched in EXos for 
negative controls. 
Samples Mode Concentration 
2CA FR6 134,1 nm 3,33 x 1010 particles/mL 21,1 particles/frame 
1AT FR6 143,0 nm 7,66 x 1010 particles/mL 48,0 particles/frame 
3AF FR5 148,7 nm 7,7 particles/frame 
 
The size of these samples varies between 134,1-148,7 nm and the concentration is in 
the order of 1010 particles/mL. It wasn’t possible to determine the concentration of fraction 
5 (FR5) of 3AF sample because the number of particles for frame was too low. Another 
dilution was not performed (a more concentrated one) due to the volume necessary for 
proteomics.  
 
3.2. Isolation and characterization of exosomes from Active-Infected Patients  
For the active group, Exos were isolated from 5 different plasma samples (100 µL). EXos 
enriched fractions from samples 5878, 3935 and 4544 were obtained by SEC using 
sepharose columns of 1 mL and characterized by bead-exosome FACS assay using 
CD71 marker, nanodrop and NTA. Results are shown in figures 36-40. 
 
 
 
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
0
200
400
600
800
1000
1200
1 2 3 4 5 6 7 8 9
O
.D
.A
b
s
 2
8
0
 n
m
F
lu
o
re
s
c
e
n
c
e
Fractions
5878
Figure 36- Protein quantification (●) by nanodrop (Abs 280 nm); Bead-based assay for FACS analysis (●) for fractions 1-
10 obtained from SEC for sample 5878 (active) and respective controls. Fr5 and Fr6 represent fractions 5 and 6 with a 
concentration of proteins of 0,056 and 0,307 μg/μL, respectively. C1 (-) -  exosomes + beads + isotype (1:5000) + 
secondary antibody; C2 (-) -  beads + Isotype (1:5000) + secondary antibody 
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Figure 37 - Protein quantification (●) by nanodrop (Abs 280 nm); Bead-based assay for FACS analysis (●) for fractions 1-
10 obtained from SEC for sample 3935 (active) and respective controls. Fr5 and Fr6 represent fractions 5 and 6 with a 
concentration of proteins of 0,283 and 1,034 μg/μL, respectively. C1 (-) -  exosomes + beads + isotype (1:5000) + 
secondary antibody; C2 (-) -  beads + Isotype (1:5000) + secondary antibody 
 
 
Figure 38 - Protein quantification (●) by nanodrop (Abs 280 nm); Bead-based assay for FACS analysis (●) for fractions 1-
10 obtained from SEC for sample 4544 (active) and respective controls. Fr4, Fr5 and Fr6 represent fractions 4, 5 and 6 
with a concentration of proteins of 0,052; 0,178 and 0,472 μg/μL, respectively. C1 (-) -  exosomes + beads + isotype 
(1:5000) + secondary antibody; C2 (-) -  beads + Isotype (1:5000) + secondary antibody 
For 5878 and 4544 samples, the fraction with EXos was fraction 5. In the case of 3935 
samples, the fraction enriches in exosomes was fraction 6. The fractions that presented 
the highest response to CD71, a marker used for the detection of EXos in plasma, were 
analyzed by nanosight (Figure 39).  
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Figure 39 - Nanosight profile for the active Leishmaniasis patients (3935 FR6; 4544 FR5; 61962 FR5 & FR6). Size and 
concentration information for the fractions with more EXos. 
Bellow we can observe the size and concentration of the samples for the fractions that 
were most enriched in exosomes (Table 3): 
Table 3- Size (mode) and concentration (particles/mL or particles/frame) of the fractions (FR) enriched in EXos for active 
Leishmaniasis plasmas 
Samples Mode Concentration 
3935 FR6 131,8 nm 1,63 x 1011 particles/mL 137,5 particles/frame 
4544 FR5 140,2 nm 3,21 x 1010 particles/mL 54,3 particles/frame 
 
The size of these samples varies between 131.8-140.2 nm and the concentration is in 
the order of 1010 or 1011 particles/mL, similarly to the negative controls. We used both 
fraction 5 and fraction 6 of sample 61962 for nanosight analysis because the bead-based 
assay wasn’t performed and we were not sure which fraction was enriched in exosomes.  
3935 FR6 4544 FR5 
61962 FR5 61962 FR6 
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3.3. Isolation and characterization of extracellular vesicles from Supernatant from L. 
infantum culture 
To evaluate the efficiency of different size sepharose columns (1 and 10 mL) on the 
recovery of EVs, SEC was performed with the supernatant from a culture with 
Leishmania infantum (Figure 41-42).  
 
Figure 41 - Results of nanodrop (●) (Abs 280 nm), bead-based assay for FACS analysis (●) and respective controls 
(fluorescence) for fractions 1-12 obtained from 10 mL column SEC for supernatant sample from Leishmania infantum 
culture. Fr10 represents fraction 10 with 0,01 μg/μL. C1 (-) -  exosomes + beads + isotype (1:5000) + secondary antibody; 
C2 (-) -  beads + Isotype (1:5000) + secondary antibody 
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Figure 40 - Results of nanodrop (Abs 280 nm) for fractions 1-8 obtained from SEC for samples 5892 and 61962 (active). 
Fractions 5 and 6 from sample 5892 contained 0,0346 and 0,288 μg/μL. Fractions 5 and 6 from sample 61962 contained 
0,128 and 0,379 μg/μL 
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Figure 42 - Results of nanodrop (●) (Abs 280 nm), bead-based assay for FACS analysis (●) and respective controls 
(fluorescence) for fractions 1-12 obtained from 1 mL column SEC for supernatant sample from Leishmania infantum 
culture. Fr5 represents fraction 5 with 0,01 μg/μL. C1 (-) -  exosomes + beads + isotype (1:5000) + secondary antibody; 
C2 (-) -  beads + Isotype (1:5000) + secondary antibody 
We can observe a peak in fraction 5 in the SEC performed with 1 mL column, suggesting 
that the most of the EVs were isolated in this fraction. In the 10 mL column, it seems that 
the EVs were isolated in fraction 9 and 10. In both cases, the protein concentration of 
these fractions is really low. These results also indicate that with 1 mL columns we can 
isolate the most of the EVs in a single fraction.  
3.4. Isolation and characterization of exosomes from Asymptomatic – Infected 
Patients 
For asymptomatic patients, we isolated the exosomes (EXos) from 3 different plasma 
samples. The isolated fractions were obtained with a 1 mL sepharose column through 
size exclusion chromatography (SEC): 
 
Figure 43 - Results of nanodrop (Abs 280 nm) for fractions 1-8 obtained from SEC for samples 608, 8844 and 621 
(asymptomatic). 
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Table 4 - Results of nanodrop for samples 608, 8844 and 621 (asymptomatic) in μg/μL. 
Samples Fraction 5 Fraction 6 
608 0 0,164 
8844 0,091 1,177 
 Fraction 6 Fraction 7 
621 0,09 0,452 
 
3.5. Isolation and characterization of exosomes from Healed patients 
For healed patients, we isolated the exosomes enriched fractions from 3 different plasma 
samples through SEC:  
 
Table 5 - Results of nanodrop for samples 3081, 64074 and 3092 (healed) in μg/μL. 
Samples Fraction 4 Fraction 5 
3092 0,045 0,335 
3081 0 0,128 
 Fraction 6 Fraction 7 
64047 0,053 0,546 
 
Both the asymptomatic group and the healed group present a similar profile (Figure 43-
44) to the other two groups, which indicate that the exosomes should be in fraction 5 or 
fraction 6. Nevertheless, bead-based assay for FACS analysis with CD71 marker should 
be performed in every sample to confirm the presence of EXos. After that, nanosight 
should also be performed to give us information about size and concentration.  
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Figure 44- Results of nanodrop (Abs 280 nm) for fractions 1-8 obtained from SEC for samples 3081, 64047 and 3092 
(healed). 
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Discussion 
The aim of this project was to develop an immunosensor for Leishmania diagnosis. For 
that, different immobilization strategies were tested. The first approach based on a work 
developed by Haddour N. et al.98 was inefficient due to the wrong description of the 
organic synthesis of NTA-pyrrole. To overcome this unsuccessful procedure, the antigen 
immobilization was done in magnetic microbeads, according the protocol used in 
cytometry52. The first results showed to be promising and further studies were done on 
the described system, such as the optimization of the hydrodynamic conditions to be 
used in Flow Injection Analysis by using a microfluidic platform. However, it was 
observed a change in the base line of the electrode potential due to a change of the 
surface because of unspecific protein immobilization. So different strategies are still 
under study to overcome the described problems.  
Other important goal to achieve in this project was the isolation of exosomes from human 
plasmas to do further characterization and proteomic analysis. Regarding the isolation 
of exosome enriched fractions with size exclusion chromatography (SEC), when we 
compare the results, it seems that the 1 mL sepharose columns can isolate de exosomes 
in only one fraction. Although the concentration of proteins is higher than usual, the 
fractions isolated in these columns are also more concentrated. So, it seems an 
advantage to use these columns to isolate samples, especially when there is little volume 
of samples, as these columns require ten times less sample to do the experiment (100 
μL of plasma). 
Other important aspect of this project was to characterize the samples with bead-based 
assay for FACS analysis and nanosight. Unfortunately, we couldn’t get the results from 
the last bead-based assay due to a failure in the FACSverse flow cytometer. 
Consequently, not all the fractions were analyzed in nanosight. We were able to do all 
the EXos isolation through SEC and to evaluate the concentration of protein in each 
sample in nanodrop.  
In the bead-based assays, the controls were quite high and in some cases, were higher 
than the signal of the fractions. It might be due to the isotype antibody, that is giving for 
some reason a high background. However, the pique is well defined and in most cases, 
is higher than the controls. 
For a matter of time and resources, the proteomic analysis will be performed in the next 
weeks, starting with 3 negative controls and 3 active patients for Leishmaniasis. From 
these results, we will be able to compare the two group and see if we can identify some 
FCUP 
Development of an innovative immunosensor for Leishmaniasis screening 
63 
 
possible biomarker. If that happens, the other samples will also be sent to proteomic 
analysis to get a more concise and accurate study. 
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Appendix 1 – Commercial Immunochromatographic Tests 
 
Manufacturer Product name Bound 
Antigen 
Application Time Leishmaniasis 
type 
Test Web site 
Bio-Rad Laboratories DiaMed-IT 
LEISH 
rK39 Human na Visceral L. IC http://www.diamed.com.br/cmi/Pagina.aspx?306 
CTK Biotech, Inc OnSite 
Leishmania Ab 
Rapid Test 
rK39 Human 15 min Visceral L. IC http://www.grupolabca.com.mx/laboratorios%20clinicos/pruebas%20rapidas/ctk%20inserts/R0122C.pdf 
Span Diagnostics, Lda Crystal KA (Kala 
azar) 
rKE16 Human 15 min MucoCutânea IC http://www.dpcleb.com/product/view/204 
InBios International Inc Kalazar 
Detect™ 
rK39 Human 10 min Visceral L. IC http://www.inbios.com/rapid-tests/kalazar-detect 
InBios International Inc Canine Visceral 
Leishmaniasis 
Dipstick* 
rK39  Dog na Visceral L. IC http://www.inbios.com/veterinary-reagent-controls/canine 
Vtrade Anigen Rapid 
Leishmania Ab 
Test Kit 
na Dog 20 min Visceral L. IC http://www.vtrade.be/nl/main/gamma/rapid-tests/test-rapide-kitvia-v600920-leishmaniose-eng.pdf 
BIONOTE Anigen Rapid 
Leishmania Ab 
Test Kit 
na Dog 20 min Visceral L. IC http://www.bionote.co.kr/ANIMAL/ENG/Production/canine.asp?LT=2&MODE=V&bIdx=165&bcIdx=9&P=2&BLT=L&PC=20&gAIdx=&gSearchText= 
Virbac Animal Health Speed Leish K Kinesin 
Capture 
Complex 
Dog 20 min Visceral L. IC http://en.bvt.fr/p-bvtfrpuben/display.aspx?srv=p-
bvtfr&typ=pub&lang=en&cmd=view&style=styles/specie.xsl&select=PRODUCT%5B@ID$eq$PRODUCT_98%5D 
Bio-
Manguinhos/Fiocruz 
DPP® Canine 
Leishmaniasis 
rK39 Dog 15 min Visceral L. IC https://www.bio.fiocruz.br/en/index.php/products/ivd-tests/rapid-tests/dppr-canine-leishmaniasis 
Biogal, Galed Labs. ImmunoRun na Dog 5-20 Visceral L. IC file:///C:/Users/camorim/Downloads/ircli155.01.12.11%20(2).pdf 
Quicking Biotech Canine 
Leishmania 
Antibody Test 
HRPO 
Conjugate 
Dog 10 min Visceral L. IC http://en.quicking.cn/Products/Pet/Canine/Enquicking12.html 
EcoDiagnóstica Leishmania Ab na Dog 10 min Visceral L. IC http://www.ecodiagnostica.com.br/produto/leishmania-ab 
